0001701541-23-000041.txt : 20230811 0001701541-23-000041.hdr.sgml : 20230811 20230811072636 ACCESSION NUMBER: 0001701541-23-000041 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 231161516 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 10-Q 1 bdtx-20230630.htm 10-Q bdtx-20230630
FALSEQ22023000170154112-31http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrentP5YP5Y00017015412023-01-012023-06-3000017015412023-08-01xbrli:shares00017015412023-06-30iso4217:USD00017015412022-12-31iso4217:USDxbrli:shares00017015412023-04-012023-06-3000017015412022-04-012022-06-3000017015412022-01-012022-06-3000017015412021-12-3100017015412022-06-300001701541us-gaap:CommonStockMember2021-12-310001701541us-gaap:AdditionalPaidInCapitalMember2021-12-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001701541us-gaap:RetainedEarningsMember2021-12-310001701541us-gaap:CommonStockMember2022-01-012022-03-310001701541us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100017015412022-01-012022-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001701541us-gaap:RetainedEarningsMember2022-01-012022-03-310001701541us-gaap:CommonStockMember2022-03-310001701541us-gaap:AdditionalPaidInCapitalMember2022-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001701541us-gaap:RetainedEarningsMember2022-03-3100017015412022-03-310001701541us-gaap:CommonStockMember2022-04-012022-06-300001701541us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001701541us-gaap:RetainedEarningsMember2022-04-012022-06-300001701541us-gaap:CommonStockMember2022-06-300001701541us-gaap:AdditionalPaidInCapitalMember2022-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001701541us-gaap:RetainedEarningsMember2022-06-300001701541us-gaap:CommonStockMember2022-12-310001701541us-gaap:AdditionalPaidInCapitalMember2022-12-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001701541us-gaap:RetainedEarningsMember2022-12-310001701541us-gaap:CommonStockMember2023-01-012023-03-310001701541us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100017015412023-01-012023-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001701541us-gaap:RetainedEarningsMember2023-01-012023-03-310001701541us-gaap:CommonStockMember2023-03-310001701541us-gaap:AdditionalPaidInCapitalMember2023-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001701541us-gaap:RetainedEarningsMember2023-03-3100017015412023-03-310001701541us-gaap:CommonStockMember2023-04-012023-06-300001701541us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001701541us-gaap:RetainedEarningsMember2023-04-012023-06-300001701541us-gaap:CommonStockMember2023-06-300001701541us-gaap:AdditionalPaidInCapitalMember2023-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001701541us-gaap:RetainedEarningsMember2023-06-300001701541bdtx:ShelfRegistrationStatementMember2022-11-142022-11-140001701541bdtx:OpenMarketSaleMember2022-11-142022-11-140001701541us-gaap:SubsequentEventMemberbdtx:FollowOnOfferingMember2023-07-052023-07-050001701541us-gaap:SubsequentEventMemberbdtx:FollowOnOfferingMember2023-07-050001701541us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001701541us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001701541us-gaap:FairValueMeasurementsRecurringMember2023-06-300001701541us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001701541us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001701541us-gaap:FairValueMeasurementsRecurringMember2022-12-310001701541us-gaap:CorporateBondSecuritiesMember2023-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001701541us-gaap:CorporateBondSecuritiesMember2022-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-3100017015412022-01-012022-12-310001701541us-gaap:EquipmentMember2023-06-300001701541us-gaap:EquipmentMember2022-12-310001701541us-gaap:FurnitureAndFixturesMember2023-06-300001701541us-gaap:FurnitureAndFixturesMember2022-12-310001701541us-gaap:OfficeEquipmentMember2023-06-300001701541us-gaap:OfficeEquipmentMember2022-12-310001701541us-gaap:LeaseholdImprovementsMember2023-06-300001701541us-gaap:LeaseholdImprovementsMember2022-12-310001701541bdtx:LaunchpadTherapeuticsIncMember2022-12-310001701541bdtx:LaunchpadTherapeuticsIncMember2023-06-30xbrli:pure0001701541bdtx:LaunchpadTherapeuticsIncMember2022-12-010001701541bdtx:LaunchpadTherapeuticsIncMember2022-01-012022-12-310001701541bdtx:A2020StockOptionPlanMember2020-01-140001701541bdtx:A2020StockOptionPlanMember2023-01-012023-01-010001701541bdtx:A2020StockOptionPlanMember2023-01-010001701541bdtx:A2020EmployeeStockPurchasePlanMember2020-01-140001701541bdtx:A2020EmployeeStockPurchasePlanMember2023-01-012023-01-010001701541us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001701541us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001701541us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001701541us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001701541bdtx:OtherAwardTypeMember2023-04-012023-06-300001701541bdtx:OtherAwardTypeMember2022-04-012022-06-300001701541bdtx:OtherAwardTypeMember2023-01-012023-06-300001701541bdtx:OtherAwardTypeMember2022-01-012022-06-300001701541bdtx:A2020StockOptionPlanMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001701541us-gaap:RestrictedStockMember2022-12-310001701541us-gaap:RestrictedStockMember2023-01-012023-06-300001701541us-gaap:RestrictedStockMember2023-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2023-06-300001701541us-gaap:PerformanceSharesMember2022-12-310001701541bdtx:PerformanceRestrictedStockUnitsMember2023-01-012023-06-300001701541us-gaap:PerformanceSharesMember2023-01-012023-06-300001701541bdtx:PerformanceRestrictedStockUnitsMember2023-06-300001701541us-gaap:PerformanceSharesMember2023-06-300001701541us-gaap:EmployeeStockMemberbdtx:A2020EmployeeStockPurchasePlanMember2023-01-012023-06-300001701541us-gaap:EmployeeStockMemberbdtx:A2020EmployeeStockPurchasePlanMember2023-06-300001701541us-gaap:EmployeeStockMemberbdtx:A2020EmployeeStockPurchasePlanMember2022-01-012022-06-300001701541us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001701541us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001701541us-gaap:RestrictedStockMember2023-01-012023-06-300001701541us-gaap:RestrictedStockMember2022-01-012022-06-300001701541us-gaap:EmployeeStockMember2023-01-012023-06-300001701541us-gaap:EmployeeStockMember2022-01-012022-06-300001701541us-gaap:PerformanceSharesMember2023-01-012023-06-300001701541us-gaap:PerformanceSharesMember2022-01-012022-06-300001701541us-gaap:WarrantMember2023-01-012023-06-300001701541us-gaap:WarrantMember2022-01-012022-06-30bdtx:contract0001701541bdtx:OperatingLeasePrincipalOfficeTwoMember2020-07-31utr:sqft0001701541bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember2020-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________________________
FORM 10-Q
_______________________________________________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED June 30, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _ TO _
COMMISSION FILE NUMBER 001-38501
___________________________________________
BLACK DIAMOND THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________________________________________________________________
Delaware81-4254660
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification No.)
One Main Street, 14th Floor
Cambridge, Massachusetts
(Address of principal executive offices)
02142
(Zip Code)
(617) 252-0848
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001BDTXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐




Non-accelerated filer☒Smaller reporting company☒






Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of August 1, 2023, the registrant had 51,575,323 shares of common stock, $0.0001 par value per share, outstanding.


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “could”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:
•the progress, timing and success of preclinical studies and our clinical trials of BDTX-1535, BDTX-4933 and any other product candidates, including the availability, timing and announcement of data and results of such studies and trials;
•the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug (IND) applications and other regulatory submissions;
•the continued development and advancement of our fibroblast growth factor receptor (FGFR) program and nomination of BDTX-4876 as our development candidate;
•our ability to obtain and maintain regulatory approval for BDTX-1535 and BDTX-4933 or any of our other current or future product candidates that we may identify or develop;
•our need to raise additional funding before we can expect to generate any revenues from product sales;
•our ability to identify future product candidates for treatment of additional disease indications;
•our ability to develop our current product candidates for the treatment of various cancers;
•the rate and degree of market acceptance and clinical utility for any current or future product candidates we may develop;
•the effects of competition with respect to BDTX-1535, BDTX-4933 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;
•the implementation of our strategic plans for our business, any product candidates we may develop and our Mutation-Allostery-Pharmacology (MAP) drug discovery engine;
•our ability to successfully develop companion diagnostics for use with our current or future product candidates;
•our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates and MAP drug discovery engine;
•our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved, and to further expand our MAP drug discovery engine;
•the period over which we expect our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements;
•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
•our future financial performance and our ability to effectively manage our anticipated growth;
•our estimates regarding the market opportunities for our product candidates, including our competitive position and the success of competing therapies that are or may become available;
2
•our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire and retain additional qualified professionals;
•the potential for our business development efforts to maximize the value of our platform and product candidates;
•the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in partnership with others;
•our ability to establish or maintain collaborations or strategic relationships and the ability and willingness of our third-party strategic collaborators to undertake research and development activities relating to our current or future product candidates;
•our expectations regarding the period during which we will remain an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the JOBS Act);
•our ability to maintain an effective system of internal controls; and
•the impact of global economic and political developments on our business, including rising inflation and capital market disruptions, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets.
Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, “Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 (the Annual Report) and in other Securities and Exchange Commission (SEC) filings. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Some of these risks and uncertainties may in the future be amplified by global health crises, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.
This Quarterly Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to this Quarterly Report. In this Quarterly Report, the terms “Black Diamond Therapeutics”, “Black Diamond”, the “Company”, “we”, “us”, “our” and similar designations refer to Black Diamond Therapeutics, Inc. and, where appropriate, our subsidiaries.
3
We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.
4
TABLE OF CONTENTS

Page
PART I - FINANCIAL INFORMATION
PART II - OTHER INFORMATION

We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not, imply a relationship with, or endorsement or sponsorship by, us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.
From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.

Part I - FINANCIAL INFORMATION
Item I. Condensed Consolidated Financial Statements (Unaudited)
Black Diamond Therapeutics, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)

As of

June 30,
2023		December 31,
2022
Assets



Current assets:



Cash and cash equivalents$41,888 

$34,315 
Investments47,639 88,492 
Prepaid expenses and other current assets3,465 

4,899 
Total current assets92,992 

127,706 
Property and equipment, net2,253 

2,587 
Restricted cash1,228 

1,168 
Right-of-use assets23,406 24,794 
Total assets$119,879 

$156,255 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$2,737 

$1,877 
Accrued expenses and other current liabilities11,161 

13,384 
Total current liabilities13,898 

15,261 
Non-current operating lease liabilities23,782 25,299 
Total liabilities37,680 

40,560 
Commitments and contingencies (Note 11)
Stockholders' equity:

Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued or outstanding at June 30, 2023 and December 31, 2022
— — 
Common stock; $0.0001 par value; 500,000,000 shares authorized at June 30, 2023 and December 31, 2022; 36,533,525 shares issued and outstanding at June 30, 2023 and 36,434,297 shares issued and outstanding at December 31, 2022
5 

5 
Additional paid-in capital457,871 

452,503 
Accumulated other comprehensive loss(661)(1,824)
Accumulated deficit(375,016)

(334,989)
Total stockholders' equity82,199 

115,695 
Total liabilities and stockholders' equity$119,879 

$156,255 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)

Three Months Ended
June 30,		Six Months Ended
June 30,

2023202220232022
Operating expenses:
Research and development$13,154 $16,195 $27,907 $33,981 
General and administrative6,878 6,978 13,686 14,871 
Total operating expenses20,032 23,173 41,593 48,852 
Loss from operations(20,032)(23,173)(41,593)(48,852)
Other income (expense):
Interest income539 386 1,161 792 
Other (expense) income341 (143)405 (377)
Total other income (expense), net880 243 1,566 415 
Net loss$(19,152)$(22,930)$(40,027)$(48,437)
Net loss per share, basic and diluted$(0.52)$(0.63)$(1.09)$(1.33)
Weighted average common shares outstanding, basic and diluted36,516,114 36,293,856 36,500,085 36,282,636 
Comprehensive loss:
Net loss$(19,152)$(22,930)$(40,027)$(48,437)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net515 (511)1,163 (1,872)
Comprehensive loss$(18,637)$(23,441)$(38,864)$(50,309)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
Six Months Ended
June 30,
2023

2022
Cash flows from operating activities:



Net loss$(40,027)$(48,437)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense5,317 6,627 
Depreciation expense236 253 
Amortization of premium on investments130 365 
Noncash rent expense1,388 1,371 
Loss on disposal of property and equipment— 3 
Loss on sale of equipment37 — 
Changes in current assets and liabilities:
Prepaid expenses and other current assets1,434 (1,751)
Other non-current assets— 6 
Accounts payable826 (1,885)
Accrued expenses and other current liabilities(2,223)(1,836)
Non-current operating lease liabilities(1,517)(1,383)
Net cash used in operating activities(34,399)(46,667)
Cash flows from investing activities:
Purchases of equipment— (200)
Proceeds from sale of equipment95 — 
Proceeds from sales and maturities of investments41,886 57,241 
Purchases of investments— (20,504)
Net cash provided by investing activities41,981 36,537 
Cash flows from financing activities:
Proceeds from exercise of common stock options and ESPP51 153 
Net cash provided by financing activities51 153 
Net increase (decrease) in cash and cash equivalents7,633 (9,977)
Cash, cash equivalents and restricted cash, beginning of period35,483 67,022 
Cash, cash equivalents and restricted cash, end of period$43,116 $57,045 
Cash and cash equivalents, end of period$41,888 $55,877 
Restricted cash, end of period1,228 1,168 
Cash, cash equivalents and restricted cash, end of period$43,116 $57,045 
Supplemental disclosure of non-cash investing and financing activities:
Purchases of equipment included in accounts payable and accrued expenses$34 $— 
Right-of-use assets obtained in exchange for operating lease obligation $— $109 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders' Equity (Unaudited)
(in thousands, except share data)

Common stock

Additional
paid-in capital

Accumulated other comprehensive income (loss)Accumulated deficit

Total
stockholders’
equity

Shares

Par Value



BALANCE - December 31, 202136,234,624 $5 $440,129 $(414)$(243,820)$195,900 
Exercise of common stock options3,565 — 11 — — 11 
Vesting of restricted stock units5,000 — — — — — 
Issuance of common stock related to ESPP31,341 — 142 — — 142 
Stock-based compensation13,038 — 3,375 — — 3,375 
Unrealized gain (loss) on investments— — — (1,361)— (1,361)
Net loss— — — — (25,507)(25,507)
BALANCE - March 31, 202236,287,568 5 443,657 (1,775)(269,327)172,560 
Vesting of restricted stock units3,333 — — — — — 
Stock-based compensation24,836 — 3,252 — — 3,252 
Unrealized gain (loss) on investments— — — (511)— (511)
Net loss— — — — (22,930)(22,930)
BALANCE - June 30, 202236,315,737 5 446,909 (2,286)(292,257)152,371 
BALANCE - December 31, 202236,434,297 $5 $452,503 $(1,824)$(334,989)$115,695 
Vesting of restricted stock units23,575 — — — — — 
Surrender of shares for taxes(3,903)— — — — — 
Issuance of common stock related to ESPP33,202 — 51 — — 51 
Stock-based compensation24,776 — 2,671 — — 2,671 
Unrealized gain (loss) on investments— — — 648 — 648 
Net loss— — — — (20,875)(20,875)
BALANCE - March 31, 202336,511,947 5 455,225 (1,176)(355,864)98,190 
Vesting of restricted stock units1,875 — — — — — 
Stock-based compensation19,703 — 2,646 — — 2,646 
Unrealized gain (loss) on investments— — — 515 — 515 
Net loss— — — — (19,152)(19,152)
BALANCE - June 30, 202336,533,525 $5 $457,871 $(661)$(375,016)$82,199 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
9
Black Diamond Therapeutics, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(Amounts in thousands, except share and per share amounts)
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $500 million. The Company simultaneously entered into an Open Market Sale AgreementSM with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of June 30, 2023, no sales have been made pursuant to the ATM Program.
On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71.6 million, after deducting underwriting discounts and commissions, as well as other offering expenses.
The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred stock and common stock. The Company expects to continue to generate operating losses for the foreseeable future.
As of August 11, 2023, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.
10
The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
The Company continues to monitor the impact of global economic developments, political unrest, high inflation, the recent failure of certain banks and financial institutions, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company’s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.

11
3. FAIR VALUE MEASUREMENTS
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at June 30, 2023 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$33,253 $— $— $33,253 
Investments:
Corporate bonds— 21,474 — 21,474 
U.S. Government agencies— 26,165 — 26,165 
Total$33,253 $47,639 $— $80,892 

Fair value measurements at December 31, 2022 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$32,278 $— $— $32,278 
Investments:
Commercial paper— 3,747 — 3,747 
Corporate bonds— 45,643 — 45,643 
U.S. Government agencies— 39,102 — 39,102 
Total$32,278 $88,492 $— $120,770 
When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument.
There were no transfers in or out of Level 3 categories in the periods presented.
12
4. INVESTMENTS
As of June 30, 2023, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Corporate bonds$21,765 $— $(291)$21,474 
U.S. Government agencies26,535 — (370)26,165 
Total$48,300 $— $(661)$47,639 
As of December 31, 2022, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$3,748 $— $(1)$3,747 
Corporate bonds46,443 — (800)45,643 
U.S. Government agencies40,125 — (1,023)39,102 
Total$90,316 $— $(1,824)$88,492 
As of June 30, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for corporate bonds with a fair value of $1,994 that had maturities of one to three years. As of June 30, 2023, all marketable securities held by the Company were in a loss position.
As of December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds, and commercial paper with a fair value of $13,687 that had maturities of one to three years. As of December 31, 2022, all marketable securities held by the Company were in a loss position.
As of June 30, 2023, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments. The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss. There have been no impairments of the Company’s assets measured and carried at fair value during the six months ended June 30, 2023 and the year ended December 31, 2022.
5. PROPERTY AND EQUIPMENT
Property and equipment, net consisted of the following:

June 30,
2023

December 31,
2022
Laboratory equipment$645 $770 
Furniture and fixtures17 17 
Computer and office equipment38 38 
Leasehold improvements2,512 2,512 
Property and equipment3,212 3,337 
Less: accumulated depreciation(959)(750)
Total Property and Equipment, net$2,253 $2,587 

Depreciation expense for the six months ended June 30, 2023 and 2022 was $236 and $253, respectively.
13
6. EQUITY METHOD INVESTMENT
In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of June 30, 2023, the Company has a 39.1% voting interest in Launchpad and one seat on Launchpad’s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company.
The Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Launchpad common shares of $2,250 in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&D) had zero basis on the Company’s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&D of $2,232 in the consolidated statements of operations and comprehensive loss. The Company also recognized a loss from investments in equity method investee of $1,540 in the consolidated statement of operations and comprehensive loss, associated with the Company’s proportionate share of Launchpad’s losses. The assets contributed by the Company were principally IPR&D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $710 was substantially related to IPR&D and immediately expensed it. As of December 31, 2022, the carrying value of the investment in Launchpad was reduced to zero. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of June 30, 2023, the carrying value of the investment in Launchpad was zero.
7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following:

June 30,
2023

December 31,
2022
Contracted research services$3,829 $4,713 
Payroll and related expenses2,998 4,648 
Professional and consulting fees1,359 1,182 
Current portion of operating lease liability2,975 2,841 
Total accrued expenses and other current liabilities$11,161 $13,384 

8. STOCK-BASED COMPENSATION
2020 Stock Option and Incentive Plan
The 2020 Stock Option and Incentive Plan (the 2020 Plan) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (IPO) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2023, 1,457,371 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2022, were added to the 2020 Plan.
14
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (the 2020 ESPP) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2023.
Stock-based compensation expense
The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2023202220232022
Stock options$2,475 $3,000 $4,930 $6,193 
Restricted stock units80 189 191 310 
Employee Stock Purchase Plan and Other91 63 196 124 

$2,646 $3,252 $5,317 $6,627 
For the six months ended June 30, 2023, the Company issued 44,479 shares of common stock out of its 2020 Plan under its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2023

202220232022
Research and development$833 

$1,526 $1,782 $3,054 
General and administrative1,813 

1,726 3,535 3,573 

$2,646 

$3,252 $5,317 $6,627 
15
Options
The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20225,359,400 $12.40 7.8$76 
Granted3,226,650 $2.70 
Cancelled or forfeited(350,424)$10.61 
Expired(68,124)$28.26 
Outstanding June 30, 20238,167,502 $8.51 8.3$11,313 
Options vested or expected to vest at June 30, 20238,167,502 $8.51 8.3$11,313 
Options exercisable at June 30, 20233,265,021 $13.61 6.9$1,610 
For the six months ended June 30, 2023, total unrecognized compensation cost related to the unvested stock-options was $15,169, which is expected to be recognized over a weighted average period of 2.2 years.
Restricted stock units
The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2023:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 2022101,397 $5.92 
Vested(15,834)$13.25 
Cancelled or forfeited(8,309)$2.14 
Unvested restricted common stock as of June 30, 202377,254 $4.82 
The total fair value of time-based restricted stock units vested during the six months ended June 30, 2023 was $210.
For the six months ended June 30, 2023, total unrecognized compensation cost related to the time-based unvested restricted stock units was $117, which is expected to be recognized over a weighted average period of 0.7 years.
The Company had 239,475 performance restricted stock units outstanding at the year ended December 31, 2022. For the six months ended June 30, 2023, the Company granted no performance restricted stock units to its employees related to the achievement of certain clinical development and/or financing milestones, released 9,616 performance restricted stock units due to the achievement of certain milestones, expired 193,000 performance restricted stock units, and had no performance restricted stock units forfeited. As of June 30, 2023, the Company had 36,859 performance restricted stock units outstanding.

Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.
16
As of June 30, 2023, for performance-based restricted stock units that were outstanding, the achievement of milestones was considered probable for 17,859 shares.
As of June 30, 2023, two milestones for outstanding performance restricted stock units were achieved. For the six months ended June 30, 2023, the Company recognized stock-based compensation expense related to these milestones of $45. The milestones that had not been met were considered not probable, and therefore no expense had been recognized related to these awards in the six months ended June 30, 2023.
Employee stock purchase plan
The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.
During the six months ended June 30, 2023 and 2022, there were 33,202 and 31,341 shares, respectively, issued under the 2020 ESPP.
9. NET LOSS PER SHARE
Net loss per share
The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):

Three Months Ended
June 30,		Six Months Ended
June 30,

2023

202220232022
Net loss$(19,152)

$(22,930)$(40,027)$(48,437)
Weighted average common shares outstanding, basic and diluted36,516,114 

36,293,856 36,500,085 36,282,636 
Net loss per share, basic and diluted$(0.52)

$(0.63)$(1.09)$(1.33)

The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
17
Six Months Ended
June 30,

20232022
Options to purchase common stock8,167,502 6,025,594 
Unvested restricted stock77,254 208,129 
Shares issuable under employee stock purchase plan102,351 27,572 
Unvested performance restricted stock units36,859 267,125 
Warrants to purchase common stock10,757 10,757 

8,394,723 6,539,177 
10. LEASES
The Company has historically entered into lease arrangements for its facilities. As of June 30, 2023, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options.
Operating leases
In July 2020, the Company entered into a seven-year agreement with an option to extend for five additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates.
In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for five additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2023 and 2022:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Lease Cost
Operating lease cost$1,054 $1,057 $2,108 $2,116 
Short-term lease cost11 21 28 40 
Variable lease cost126 219 382 476 
Sublease income(335)— (470)— 
Total lease cost$856 $1,297 $2,048 $2,632 
18
Other Operating Lease InformationJune 30, 2023June 30, 2022
Cash paid for amounts included in the measurement of lease liability$2,103 $1,290 
Weighted-average remaining lease term7.48.3
Weighted-average discount rate5.3 %5.3 %
The variable lease costs for the three and six months ended June 30, 2023 and 2022 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
Future minimum lease payments under the Company’s operating leases as of June 30, 2023 were as follows:
As of June 30, 2023
2023 (excluding the six months ended June 30, 2023)
$2,141 
20244,359 
20254,477 
20264,599 
20274,724 
Thereafter12,250 
Total lease payments32,550 
Less: interest(5,793)
Total lease liability$26,757 

11. COMMITMENTS AND CONTINGENCIES
The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.
License agreements
The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2023, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2023 or December 31, 2022.
19
Legal proceedings
The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
12. BENEFIT PLANS
The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three and six months ended June 30, 2023 and 2022, the Company contributed $167, $543, $199 and $757, respectively, to the 401(k) Plan.
13. SUBSEQUENT EVENTS
On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71,565, after deducting underwriting discounts and commissions, as well as other offering expenses.
20
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2022, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 9, 2023. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in our Annual Report on Form 10-K and in other SEC filings.
Overview
We are a clinical-stage precision oncology medicine company focused on pioneering the discovery and development of novel MasterKey therapies. We target families of oncogenic mutations in patients with genetically defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology (MAP) drug discovery engine, is designed to allow us to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Our goal is to identify families of mutations that can be inhibited with MasterKey therapies, thereby providing precision oncology to greater numbers of patients with genetically defined tumors.
Our lead product candidate, BDTX-1535, is designed to be a brain penetrant, mutant selective and irreversible fourth generation MasterKey inhibitor of a family of oncogenic mutations in the ErbB-1 epidermal growth factor receptor (EGFR) which are resistant to current generation tyrosine kinase inhibitors (TKIs), while sparing wild type EGFR (EGFR WT) activity. On June 27, 2023, we announced initial clinical data from the dose escalation portion of the Phase 1 clinical study of BDTX-1535, demonstrating a favorable tolerability profile and clinical proof of activity of BDTX-1535 in non-small cell lung cancer (NSCLC) patients harboring acquired resistance and intrinsic driver EGFR mutations. Confirmed radiographic partial response (PR) by RECIST 1.1 was achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in a subgroup, who had measurable disease at study start, and underwent post-baseline tumor assessment by RECIST1.1. One additional patient had an unconfirmed PR, while the remaining six patients had stable disease. Confirmed PRs were observed in NSCLC patients with a wide range of EGFR mutations including classical and intrinsic driver mutations and acquired C797S resistance mutation, as well as complex mutations that include a combination of classical, intrinsic, and acquired resistance mutations. Two NSCLC patients demonstrated radiographic improvement in the peripheral disease and central nervous system (CNS) metastases.
BDTX-1535 was generally well tolerated by NSCLC and glioblastoma multiforme (GBM) patients and the overall safety profile was consistent with the EGFR TKI class of drugs. The most common drug-related adverse events were mild to moderate rash, diarrhea, stomatitis, paronychia, nausea and fatigue. No patients experienced dose limiting toxicity at 15-200 mg once-daily (QD) doses. One of 15 patients treated at the 300 mg QD dose experienced dose limiting diarrhea and 5 of 12 patients at the 400 mg QD dose experienced dose limiting toxicity (diarrhea, 2 patients; rash, stomatitis, fatigue and decreased appetite, 1 patient each). No unexpected safety signal was identified during dose escalation.
We expect to provide an update on the Phase 1 dose escalation data in the cohort of patients with GBM in the fourth quarter of 2023. Expansion cohorts initiated in July 2023 to assess overall response rate (ORR) by RECIST 1.1 in NSCLC patients with EGFR acquired resistance mutations after progression on a third generation EGFR TKI and intrinsic driver mutations after progression on an EGFR TKI.
21
Our second product candidate, BDTX-4933, is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations, such as RAS mutations, which has the potential to avoid paradoxical activation. We initiated a Phase 1 clinical trial for BDTX-4933 in select indications for patients harboring all-class BRAF or RAS mutations in the second quarter of 2023. We are also leveraging our MAP drug discovery engine to identify other families of oncogenic mutations in validated oncogenes, which have the potential to expand the reach of MasterKey therapies.
We have selected a development candidate, BDTX-4876, for our fibroblast growth factor receptor (FGFR) program. BDTX-4876 is selective against MasterKey mutations and alterations in FGFR 2 and 3, while sparing FGFR 1 and 4. We plan to evaluate strategic alternatives for BDTX-4876 as we deepen our focus on our two clinical stage assets. We expect one other undisclosed program in solid tumors to progress to development candidate nomination in 2023.
Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights while conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.
To date, we have funded our operations with proceeds from the sale of preferred stock and common stock. Since inception, we have incurred significant operating losses. Our net losses were $40.0 million and $48.4 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, we had an accumulated deficit of $375.0 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:
•advance clinical studies for BDTX-1535 and BDTX-4933 and continue preclinical studies for our other product candidates;
•continue to identify additional product candidates from our proprietary MAP drug discovery engine;
•obtain, maintain, expand and protect our intellectual property portfolio;
•attract and retain key clinical, scientific, management and commercial personnel;
•seek marketing approvals for our product candidates that successfully complete clinical trials, if any; and
•acquire or in-license additional product candidates.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates, delay our pursuit of potential in-licenses or acquisitions, and reduce headcount and general and administrative costs.
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
22
Additionally, we continue to actively monitor macroeconomic conditions and market volatility resulting from global economic developments, political unrest, high inflation, the recent failure of certain banks and financial institutions, and health crises. While we believe such factors have had no significant impact on our business or financial results during the periods presented, future developments and potential impacts on our business are uncertain and cannot be predicted with confidence.
As of June 30, 2023, we had cash, cash equivalents and investments of approximately $89.5 million. We believe that the net proceeds from our Follow-on Offering in July 2023, together with our existing cash, cash equivalents and investments, will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “—Liquidity and capital resources.” To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives.
Components of our results of operations
Revenue
To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.
Operating expenses
Research and development expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:
•expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval;
•expenses incurred under agreements with contract research organizations, or CROs, that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and contract manufacturing organizations, or CMOs, that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs;
•other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;
•payments made in cash or equity securities under third-party licensing, acquisition and option agreements;
•employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
•costs related to compliance with regulatory requirements; and
•allocated facilities-related costs, depreciation and other expenses, which include rent and utilities.
23
We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Any nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.
Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under license, acquisition and option agreements. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program.
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our clinical trials for BDTX-1535 and BDTX-4933, as well as conduct other preclinical and clinical development, including submitting regulatory filings for other product candidates.
We expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above current year levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.
At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following:
•the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;
•establishing an appropriate safety and efficacy profile with IND-enabling studies;
•successful patient enrollment in and the initiation and completion of clinical trials;
•the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (FDA) and non-U.S. regulators;
•the extent of any required post-marketing approval commitments to applicable regulatory authorities;
•establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;
•development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;
•obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
24
•significant and changing government regulation;
•launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and
•maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.
Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.
General and administrative expenses
General and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, business development, finance, human resources, legal, information technology, pre-commercial and support personnel functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates and prepare for potential commercialization activities. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate.
Other income (expense)
Other income (expense) consists primarily of interest income earned on our cash equivalents and investment balances, sublease income, realized and unrealized foreign currency transaction gains and losses, and gain (loss) on sale of IP related to equity method investment.
Equity in (losses) of unconsolidated entity
Equity in (losses) of unconsolidated entity consists of our share of equity method investee losses on the basis of our equity ownership percentage and IPR&D charges resulting from basis differences.
25
Results of operations
Comparison of the three months ended June 30, 2023 and 2022
The following table summarizes our results of operations for the three months ended June 30, 2023 and 2022:

Three Months Ended
June 30,



2023

2022

Change

(in thousands)
Operating expenses:
Research and development$13,154 $16,195 $(3,041)
General and administrative6,878 6,978 (100)
Total operating expenses20,032 23,173 (3,141)
Loss from operations(20,032)(23,173)3,141 
Other income (expense):
Interest income539 386 153 
Other (expense) income341 (143)484 
Total other income (expense), net880 243 637 
Net loss$(19,152)$(22,930)$3,778 
Research and development
Research and development expenses were $13.2 million for the three months ended June 30, 2023, compared to $16.2 million for the three months ended June 30, 2022. The following table summarizes our research and development expenses for the three months ended June 30, 2023 and 2022:

Three Months Ended
June 30,



2023

2022

Change

(in thousands)
BDTX-1535 research and development expenses$3,428 $1,089 $2,339 
BDTX-4933 research and development expenses1,718 168 1,550 
BDTX-189 research and development expenses— 2,561 (2,561)
Other research programs and platform development expenses2,106 5,021 (2,915)
Personnel expenses4,670 5,968 (1,298)
Allocated facility expenses790 974 (184)
Other expenses442 414 28 
$13,154 $16,195 $(3,041)
The decrease of $3.0 million for the three months ended June 30, 2023 was primarily due to a net increase of $3.9 million related to the progression of our clinical trials for BDTX-1535 and BDTX-4933 offset by decreased spend relating to other research programs and platform development of $2.9 million due to reduced spending on early discovery projects, compared to the three months ended June 30, 2022. In addition, BDTX-189 expenses decreased $2.6 million due to the discontinuation of the development of BDTX-189 to focus on upcoming milestones for our pipeline programs, BDTX-1535 and BDTX-4933. Personnel expenses decreased $1.3 million as a result of the realignment of our workforce in April 2022 to focus on upcoming milestones for our pipeline programs.
26
General and administrative
General and administrative expenses were $6.9 million for the three months ended June 30, 2023 compared to $7.0 million for the three months ended June 30, 2022. This was primarily a result of a decrease in personnel-related costs, legal and other professional fees.
Other income (expense)
Other income was $0.9 million for the three months ended June 30, 2023, compared to $0.2 million for the three months ended June 30, 2022. The increase was primarily attributable to amortization of premium on investments decreasing at a higher rate in 2023 compared to 2022, sublease income in 2023 and interest income increasing due to market conditions.
Comparison of the six months ended June 30, 2023 and 2022
The following table summarizes our results of operations for the six months ended June 30, 2023 and 2022:

Six Months Ended
June 30,



2023

2022

Change

(in thousands)
Operating expenses:
Research and development$27,907 $33,981 $(6,074)
General and administrative13,686 14,871 (1,185)
Total operating expenses41,593 48,852 (7,259)
Loss from operations(41,593)(48,852)7,259 
Other income (expense):
Interest income1,161 792 369 
Other (expense) income405 (377)782 
Total other income (expense), net1,566 415 1,151 
Net loss$(40,027)$(48,437)$8,410 
Research and development
Research and development expenses were $27.9 million for the six months ended June 30, 2023, compared to $34.0 million for the six months ended June 30, 2022. The following table summarizes our research and development expenses for the six months ended June 30, 2023 and 2022:

Six Months Ended
June 30,



2023

2022

Change

(in thousands)
BDTX-1535 research and development expenses$7,161 $2,477 $4,684 
BDTX-4933 research and development expenses3,397 204 3,193 
BDTX-189 research and development expenses— 5,044 (5,044)
Other research programs and platform development expenses4,893 10,518 (5,625)
Personnel expenses9,779 12,905 (3,126)
Allocated facility expenses1,799 2,005 (206)
Other expenses878 828 50 
$27,907 $33,981 $(6,074)
27
The decrease of $6.1 million for the six months ended June 30, 2023 was primarily due to a decrease of $5.0 million in BDTX-189 expenses due to the discontinuation of the development of BDTX-189 to focus on upcoming milestones for our pipeline programs, BDTX-1535 and BDTX-4933, compared to the six months ended June 30, 2022. Additionally, there was a net increase of $7.9 million related to the progression of our clinical trials for BDTX-1535 and BDTX-4933 offset by decreased spend relating to other research programs and platform development of $5.6 million due to reduced spending on early discovery projects. Personnel expenses decreased $3.1 million as a result of the realignment of our workforce in April 2022 to focus on upcoming milestones for our pipeline programs.
General and administrative
General and administrative expenses were $13.7 million for the six months ended June 30, 2023 compared to $14.9 million for the six months ended June 30, 2022. This was primarily a result of a decrease in personnel-related costs, legal and other professional fees.
Other income (expense)
Other income was $1.6 million for the six months ended June 30, 2023, compared to $0.4 million for the six months ended June 30, 2022. The increase was primarily attributable to amortization of premium on investments decreasing at a higher rate in 2023 compared to 2022, sublease income in 2023 and interest income increasing due to market conditions.
Liquidity and capital resources
Sources of liquidity
Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of common and preferred stock.
On February 3, 2020, we completed an IPO of 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231.3 million. We received $212.1 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. Through June 30, 2023, we had received net cash proceeds of $200.6 million from previous sales of our preferred stock and as of June 30, 2023, we had cash, cash equivalents and investments of $89.5 million.
On November 14, 2022, we filed a shelf registration statement on Form S-3 (the Shelf Registration Statement) with the SEC, which covers the offering, issuance and sale of our common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum price of $500 million. We simultaneously entered into an Open Market Sale AgreementSM (the Sales Agreement) with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by us of up to $150 million of our common stock, or the Shares, from time to time through Jefferies as our sales agent (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. We may sell the Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Sales Agreement, but we have no obligation to sell any Shares under the Sales Agreement. We or Jefferies may suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. As of June 30, 2023, no sales have been made pursuant to the ATM Program.
28
On July 5, 2023, we completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of our common stock at a price to the public of $5.00. The aggregate net proceeds from the Follow-on Offering totaled approximately $71.6 million after deducting underwriting discounts and commissions, as well as other offering expenses. The underwriters did not exercise any portion of their 30-day overallotment option to purchase up to an additional 2,250,000 shares of the Company’s common stock at the public offering price, which expired on July 29, 2023, and therefore no additional proceeds from the Follow-on Offering were received.
Cash flows
The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):

Six Months Ended
June 30,

2023

2022
Cash used in operating activities$(34,399)

$(46,667)
Cash provided by investing activities
41,981 

36,537 
Cash provided by financing activities
51 

153 
Net increase (decrease) in cash and cash equivalents
$7,633 

$(9,977)
Operating activities
During the six months ended June 30, 2023, we used cash in operating activities of $34.4 million, primarily resulting from our net loss of $40.0 million, partially offset by the non-cash charge related to stock compensation expense of $5.3 million.
During the six months ended June 30, 2022, we used cash in operating activities of $46.7 million, primarily resulting from our net loss of $48.4 million, partially offset by the non-cash charge related to stock compensation expense of $6.6 million.
Changes in accounts payable and accrued expenses in all periods were generally due to growth in our business, the advancement of our product candidates and the timing of vendor invoicing and payments.
Investing activities
During the six months ended June 30, 2023, we had cash provided by investing activities of $42.0 million primarily from the sales and maturities of investments.
During the six months ended June 30, 2022, we had cash provided by investing activities of $36.5 million primarily from the sales and maturities of investments.
Financing activities
During the six months ended June 30, 2023, we had cash provided by financing activities of $0.1 million, consisting of proceeds from the participation in the employee stock purchase plan.
During the six months ended June 30, 2022, we had cash provided by financing activities of $0.2 million consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan.
29
Funding requirements
We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:

•advance BDTX-1535 and BDTX-4933 through clinical trials;
•advance preclinical development of our early stage programs, including our FGFR program;
•manufacture, or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late state and commercial manufacturing;
•seek regulatory approvals for any product candidates that successfully complete clinical trials;
•establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;
•hire additional clinical, quality control and scientific personnel; and
•obtain, maintain, expand and protect our intellectual property portfolio.
As of June 30, 2023, we had cash, cash equivalents and investments of $89.5 million. We believe that the net proceeds from our Follow-on Offering in July 2023, together with our existing cash, cash equivalents and investments, will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.

Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to further reduce or terminate our operations. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:
•the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;
•the costs, timing and outcome of regulatory review of our product candidates;
•the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials;
•the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
•subject to receipt of regulatory approval, the costs of commercialization activities for our product candidates, to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
•the ability to receive additional non-dilutive funding;
•the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;
30
•the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;
•our ability to establish and maintain collaborations on favorable terms, if at all;
•the extent to which we acquire or in-license other product candidates and technologies; and
•the costs of operating as a public company.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time, if ever, as we can generate substantial product revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties or through other sources of financing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. However, the trading prices for our common stock and for other biopharmaceutical companies have been highly volatile. As a result, we may face difficulties raising capital through sales of our common stock, and such sales may be on unfavorable terms. Similarly, adverse macroeconomic conditions and market volatility resulting from global economic developments, political unrest, high inflation, global health crises, or other factors could materially and adversely affect our ability to consummate an equity or debt financing on favorable terms or at all. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all.
To the extent that we raise additional capital through the sale of private or public equity or convertible debt securities, the ownership interest of our stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. In addition, debt financing may involve significant cash payment obligations and specific financial ratios that may restrict our ability to operate our business would result in fixed payment obligations.
If we raise additional funds through collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, obtain capital through arrangements with collaborators on terms unfavorable to us or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of our stockholders.
Contractual obligations and commitments
The following summarizes our contractual obligations as of June 30, 2023:

Payments Due by Period

Less than 1 Year1 to 3 Years3 to 5 YearsMore than 5 Years

Total
(in thousands)
Property leases - commenced
$4,301 $8,955 $9,449 $9,845 $32,550 
Total
$4,301 $8,955 $9,449 $9,845 

$32,550 
31
Property leases – commenced
The amounts reported for property leases represent future minimum lease payments under non-cancelable operating leases in effect as of June 30, 2023. The minimum lease payments do not include common area maintenance charges or real estate taxes.
Other contractual obligations
The contractual obligations table does not include any potential future milestone payments or royalty payments we may be required to make under our existing license agreements due to the uncertainty of the occurrence of the events requiring payment under those agreements.
Critical accounting policies and significant judgments and use of estimates
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations— Critical Accounting Policies and Use of Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 9, 2023. During the six months ended June 30, 2023, there were no material changes to our critical accounting policies from those previously disclosed.
Recently issued accounting pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.
Emerging growth company and smaller reporting company status
The Jumpstart Our Business Startups Act of 2012 (the JOBS Act) permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to not “opt out” of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company.
We are also a “smaller reporting company” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
32
Item 3. Quantitative and Qualitative Disclosure About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2023.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
33
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
The information required with respect to this item can be found under “Legal Proceedings” in Note 11 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q and is incorporated by reference into this Item 1. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Item 1A. Risk Factors
We are updating and supplementing our risk factors previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 9, 2023 to add the following new risk factor:
Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results.
Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, the Federal Deposit Insurance Corporation took control and was appointed receiver of Silicon Valley Bank, or SVB, after it was unable to continue its operations. This event exposed vulnerabilities in the banking sector, including legal uncertainties, significant volatility and contagion risk, and caused market prices of regional bank stocks to plummet.
As of the date of this Quarterly Report on Form 10-Q, we do not hold material cash deposits at SVB and have not experienced any adverse impact to our liquidity or to our current and projected business operations, financial condition, or results of operations; however, we are unable to predict the extent or nature of the impacts of evolving circumstances in the financial services industry at this time. If, for example, other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened. While it is not possible at this time to predict the extent of the impact that high market volatility and instability of the banking sector could have on economic activity and our business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.
There have been no other material changes to the risk factors previously disclosed in Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K for the year ended December 31, 2022. Please refer to the complete Part I, Item 1A of our Annual Report for additional risks and uncertainties we are facing that may have a material adverse effect on our business prospects, financial condition and results of operations. In addition to the risks described in our Annual Report on Form 10-K, you should carefully consider the other information set forth in this Form 10-Q and the information in our other filings with the SEC, as they could materially affect our business, financial condition or future results of operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Recent Sales of Unregistered Equity Securities
None.
34
Use of Proceeds from IPO of Common Stock
On February 3, 2020, we completed the IPO of our common stock pursuant to which we issued and sold 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share.
The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-235789), which was declared effective by the SEC on January 29, 2020. J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and Canaccord Genuity LLC acted as joint book-running managers of the offering and as representatives of the underwriters.
We received aggregate gross proceeds from our IPO of $231.3 million, or aggregate net proceeds of $212.1 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.

There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on January 30, 2020.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Not applicable.
35

Item 6. Exhibits
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report.
Exhibit
No.

Exhibit Index
31.1*
31.2*
32.1*+
101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH

Inline XBRL Taxonomy Extension Schema Document.
101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB

Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.
104Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)
*

Filed herewith.
+

This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

36
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Black Diamond Therapeutics, Inc.



Date: August 11, 2023By:
/s/ David M. Epstein


David M. Epstein
President and Chief Executive Officer
(Principal Executive Officer)

Black Diamond Therapeutics, Inc.



Date: August 11, 2023By:
/s/ Fang Ni


Fang Ni
Chief Business Officer and Chief Financial Officer
(Principal Financial Officer)

37
 EX-31.1 2 exhibit311_q22023.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(a) OR 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, David M. Epstein, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2023 of Black Diamond Therapeutics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and



5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 11, 2023
           By: /s/ David M. Epstein
  
David M. Epstein
President, Chief Executive Officer
and Director
(Principal Executive Officer)








 EX-31.2 3 exhibit312_q22023.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) OR 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, Fang Ni, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2023 of Black Diamond Therapeutics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and



5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 11, 2023
By:/s/ Fang Ni
  
Fang Ni
Chief Business Officer and Chief Financial Officer
(Principal Financial Officer)








 EX-32.1 4 exhibit321_q22023.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, David M. Epstein, the Principal Executive Officer, and Fang Ni, the Principal Financial Officer, of Black Diamond Therapeutics, Inc. (the “Company”), hereby certify, that, to their knowledge:

(1)the Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 11, 2023
By:/s/ David M. Epstein
  
David M. Epstein
President, Chief Executive Officer
and Director
(Principal Executive Officer)






Date: August 11, 2023
By:/s/ Fang Ni
  
Fang Ni
Chief Business Officer and Chief Financial Officer
(Principal Financial Officer)








 EX-101.SCH 5 bdtx-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - EQUITY METHOD INVESTMENT link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - INVESTMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - EQUITY METHOD INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - BENEFIT PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bdtx-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 bdtx-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bdtx-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Professional and consulting fees Accrued Professional Fees, Current Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Total current assets Assets, Current Research and development Research and Development Expense Changes in current assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Open Market Sale Open Market Sale [Member] Open Market Sale Award Type [Domain] Award Type [Domain] Research and development asset acquired other than through business combination, written-off Research and Development Asset Acquired Other than Through Business Combination, Writeoff Investment, Name [Domain] Investment, Name [Domain] Expired performance restricted stock units (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Units outstanding (in shares) Unvested restricted common stock, beginning balance (in shares) Unvested restricted common stock, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Amortization of premium on investments Investment Income, Net, Amortization of Discount and Premium Other (expense) income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Investments, Debt and Equity Securities [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Employer contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount Equity Method Investments and Joint Ventures [Abstract] Unvested performance restricted stock units Performance Shares [Member] Sale of stock, authorized consideration Sale of Stock, Authorized Consideration Sale of Stock, Authorized Consideration Accounts payable Accounts Payable, Current Options exercisable, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Investment, Name [Axis] Investment, Name [Axis] Purchases of investments Payments to Acquire Investments Total other income (expense), net Nonoperating Income (Expense) Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Commitments and contingencies Commitments and Contingencies Lessee, Operating Lease, Liability, to be Paid [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Proceeds from equity financing Proceeds from Issuance or Sale of Equity Area leased (square feet) Lessee, Operating Lease, Area Lessee, Operating Lease, Area Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Options vested or expected to vest, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Other non-current assets Increase (Decrease) in Other Noncurrent Assets EQUITY METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Investments Debt Securities, Available-for-Sale, Current NATURE OF BUSINESS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Loss on disposal of property and equipment Gain (Loss) on Disposal of Property and Equipment Gain (Loss) on Disposal of Property and Equipment Furniture and fixtures Furniture and Fixtures [Member] Current liabilities: Liabilities, Current [Abstract] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued or outstanding at June 30, 2023 and December 31, 2022 Preferred Stock, Value, Issued Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Net loss per share, diluted (in dollars per share) Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Unvested restricted stock Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Options vested or expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Level 3 Fair Value, Inputs, Level 3 [Member] Subsequent Events [Abstract] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol(s) Trading Symbol Letter of credit outstanding Letters of Credit Outstanding, Amount U.S. Government agencies U.S. Government agencies US Government Agencies Debt Securities [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Investments: Investments, Fair Value Disclosure Level 2 Fair Value, Inputs, Level 2 [Member] Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company LEASES Lessee, Operating Leases [Text Block] Noncash rent expense Rent Expense Rent Expense Corporate bonds Corporate bonds Corporate Bond Securities [Member] 2020 Stock Option Plan 2020 Stock Option Plan [Member] 2020 Stock Option Plan Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Entity Ex Transition Period Entity Ex Transition Period Shares issuable under employee stock purchase plan Employee Stock [Member] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders' equity: Equity, Attributable to Parent [Abstract] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Exercise of common stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Computation of Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Launchpad Therapeutics, Inc. Launchpad Therapeutics, Inc. [Member] Launchpad Therapeutics, Inc. Common stock Common Stock [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Shelf Registration Statement Shelf Registration Statement [Member] Shelf Registration Statement City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code NET LOSS PER SHARE Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Document Fiscal Year Focus Document Fiscal Year Focus Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Lease term (in years) Lessee, Operating Lease, Term of Contract Entity Small Business Entity Small Business Local Phone Number Local Phone Number Property and equipment, net Total Property and Equipment, net Property, Plant and Equipment, Net Increase of authorized shares, percent of common stock outstanding Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Statement of Cash Flows [Abstract] Warrants to purchase common stock Warrant [Member] Assets Assets [Abstract] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Restricted stock units Restricted Stock Units (RSUs) [Member] Accounts payable Increase (Decrease) in Accounts Payable, Trade Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Depreciation expense Depreciation Retirement Benefits [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Unrealized gain (loss) on investments, net Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Accumulated deficit Retained Earnings [Member] Schedule of Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities and stockholders' equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Net loss per share, basic (in dollars per share) Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation cost, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Issuance of common stock related to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Payables and Accruals [Abstract] 2023 (excluding the six months ended June 30, 2023) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Summary of Lease Cost and Other Operating Lease Information Lease, Cost [Table Text Block] Entity Address, City or Town Entity Address, City or Town Research and development Research and Development Expense [Member] Options vested or expected to vest, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Principles of consolidation Consolidation, Policy [Policy Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Document Quarterly Report Document Quarterly Report Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Purchases of equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Follow-on Offering Follow-on Offering [Member] Follow-on Offering Document Transition Report Document Transition Report General and administrative General and Administrative Expense [Member] Property and equipment Property, Plant and Equipment, Gross Options outstanding, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of estimates Use of Estimates, Policy [Policy Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Fair Value Debt Securities, Available-for-Sale ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liability Operating Lease, Liability, Current Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, Plant and Equipment [Abstract] Issuance of common stock related to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Proceeds from sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Adjustment to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Fair value of units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Stock price (in dollars per share) Sale of Stock, Price Per Share Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost Additional paid-in capital Additional Paid in Capital Common stock, shares issued (in shares) Common Stock, Shares, Issued Units vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Name of each exchange on which registered Security Exchange Name Total Assets, Fair Value Disclosure Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Stock options Options to purchase common stock Employee Stock Option [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Employer contribution, matching contribution percentage Defined Contribution Plan, Employer Matching Contribution, Percent of Match Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Forfeited (in shares) Cancelled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unrecognized compensation cost, recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of leases Lessee, Operating Lease, Number Of Contracts Lessee, Operating Lease, Number Of Contracts Employer contribution, percent of each participant's salary Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Options outstanding, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Award purchase period (in months) Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Short-term lease cost Short-Term Lease, Cost Impairment of fair value assets Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded Stock-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Proceeds from sale of equipment Proceeds from Sale of Property, Plant, and Equipment Subsequent Event [Table] Subsequent Event [Table] Lease Contractual Term [Axis] Lease Contractual Term [Axis] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Principles of consolidation and unaudited interim financial information Basis of Accounting, Policy [Policy Text Block] Document Period End Date Document Period End Date Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Four Lessee, Operating Lease, Liability, Payments, Due after Year Four Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Subsequent Event Subsequent Event [Member] Maximum employee subscription rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Restricted cash Restricted cash, end of period Restricted Cash, Noncurrent Stock-based compensation expense Share-Based Payment Arrangement, Expense Contracted research services Accrued Contract Research Service Fees, Current Accrued Contract Research Service Fees, Current Canceled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of each class Title of 12(b) Security Payroll and related expenses Employee-related Liabilities, Current FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] 2020 ESPP 2020 Employee Stock Purchase Plan [Member] 2020 Employee Stock Purchase Plan Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Sublease income Sublease Income Unvested restricted common stock, beginning balance (in dollars per share) Unvested restricted common stock, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Amendment Flag Amendment Flag Other Operating Lease Information Lease, Other Information [Abstract] Lease, Other Information [Abstract] Loss on sale of equipment Gain (Loss) on Sale of Equipment Gain (Loss) on Sale of Equipment Money market funds Money Market Funds [Member] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Performance Restricted Stock Units Performance Restricted Stock Units [Member] Performance Restricted Stock Units Equity method investment Equity Method Investments Employee Stock Purchase Plan and Other Other Award Type [Member] Other Award Type Cash and cash equivalents Cash and cash equivalents, end of period Cash and Cash Equivalents, at Carrying Value Surrender of shares for taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total lease cost Lease, Cost Shares issued under share-based compensation plan Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Assets: Assets, Fair Value Disclosure [Abstract] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Leasehold improvements Leasehold Improvements [Member] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Supplemental disclosure of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses: Operating Expenses [Abstract] Purchases of equipment Payments to Acquire Property, Plant, and Equipment Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Additional paid-in capital Additional Paid-in Capital [Member] Current assets: Assets, Current [Abstract] Leases [Abstract] Lease Cost Lease, Cost [Abstract] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Loss recognized from equity method investment Income (Loss) from Equity Method Investments Entity Address, State or Province Entity Address, State or Province Fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three Cover [Abstract] Laboratory equipment Equipment [Member] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Commercial paper Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Interest income Investment Income, Nonoperating Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] SUBSEQUENT EVENTS Subsequent Events [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Non-current operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities Cash paid for amounts included in the measurement of lease liability Operating Lease, Payments Recurring Fair Value, Recurring [Member] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Total lease payments Lessee, Operating Lease, Liability, to be Paid Other income (expense): Other Income and Expenses [Abstract] BENEFIT PLANS Compensation and Employee Benefit Plans [Text Block] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Total operating expenses Operating Expenses Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Lease term, optional extension (in years) Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Maximum percent of fair market value of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Total lease liability Operating Lease, Liability Loss from operations Operating Income (Loss) Achievement of milestones probable ( in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable Maximum employee subscription amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Total liabilities Liabilities Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Computer and office equipment Office Equipment [Member] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Gain on sale of IP Gain (Loss) on Disposition of Intangible Assets Measurement Frequency [Domain] Measurement Frequency [Domain] PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Common shares received from equity method investment (in shares) Equity Method Investment, Shares Received in Noncash Exchange Equity Method Investment, Shares Received in Noncash Exchange Principal office, lease two Operating Lease, Principal Office, Two [Member] Operating Lease, Principal Office, Two Right-of-use assets obtained in exchange for operating lease obligation Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Proceeds from exercise of common stock options and ESPP Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Statement [Line Items] Statement [Line Items] Plan Name [Axis] Plan Name [Axis] Options vested or expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Operating Lease, Office and Laboratory Space, NY Operating Lease, Office and Laboratory Space, NY [Member] Operating Lease, Office and Laboratory Space, NY Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Weighted Average Remaining Life and Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Schedule of Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Common stock; $0.0001 par value; 500,000,000 shares authorized at June 30, 2023 and December 31, 2022; 36,533,525 shares issued and outstanding at June 30, 2023 and 36,434,297 shares issued and outstanding at December 31, 2022 Common Stock, Value, Issued General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] EX-101.PRE 9 bdtx-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page - shares
 6 Months Ended
Jun. 30, 2023
Aug. 01, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-38501  
Entity Registrant Name BLACK DIAMOND THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-4254660  
Entity Address, Address Line One One Main Street, 14th Floor  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02142  
City Area Code (617)  
Local Phone Number 252-0848  
Title of each class Common stock, par value $0.0001  
Trading Symbol(s) BDTX  
Name of each exchange on which registered NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   51,575,323
Amendment Flag false  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Entity Central Index Key 0001701541  
Current Fiscal Year End Date --12-31  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 41,888 $ 34,315
Investments 47,639 88,492
Prepaid expenses and other current assets 3,465 4,899
Total current assets 92,992 127,706
Property and equipment, net 2,253 2,587
Restricted cash 1,228 1,168
Right-of-use assets 23,406 24,794
Total assets 119,879 156,255
Current liabilities:    
Accounts payable 2,737 1,877
Accrued expenses and other current liabilities 11,161 13,384
Total current liabilities 13,898 15,261
Non-current operating lease liabilities 23,782 25,299
Total liabilities 37,680 40,560
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued or outstanding at June 30, 2023 and December 31, 2022 0 0
Common stock; $0.0001 par value; 500,000,000 shares authorized at June 30, 2023 and December 31, 2022; 36,533,525 shares issued and outstanding at June 30, 2023 and 36,434,297 shares issued and outstanding at December 31, 2022 5 5
Additional paid-in capital 457,871 452,503
Accumulated other comprehensive loss (661) (1,824)
Accumulated deficit (375,016) (334,989)
Total stockholders' equity 82,199 115,695
Total liabilities and stockholders' equity $ 119,879 $ 156,255
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares outstanding (in shares) 0 0
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 36,533,525 36,434,297
Common stock, shares outstanding (in shares) 36,533,525 36,434,297
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:        
Research and development $ 13,154 $ 16,195 $ 27,907 $ 33,981
General and administrative 6,878 6,978 13,686 14,871
Total operating expenses 20,032 23,173 41,593 48,852
Loss from operations (20,032) (23,173) (41,593) (48,852)
Other income (expense):        
Interest income 539 386 1,161 792
Other (expense) income 341 (143) 405 (377)
Total other income (expense), net 880 243 1,566 415
Net loss $ (19,152) $ (22,930) $ (40,027) $ (48,437)
Net loss per share, basic (in dollars per share) $ (0.52) $ (0.63) $ (1.09) $ (1.33)
Net loss per share, diluted (in dollars per share) $ (0.52) $ (0.63) $ (1.09) $ (1.33)
Weighted average common shares outstanding, basic (in shares) 36,516,114 36,293,856 36,500,085 36,282,636
Weighted average common shares outstanding, diluted (in shares) 36,516,114 36,293,856 36,500,085 36,282,636
Comprehensive loss:        
Net loss $ (19,152) $ (22,930) $ (40,027) $ (48,437)
Other comprehensive income (loss):        
Unrealized gain (loss) on investments, net 515 (511) 1,163 (1,872)
Comprehensive loss $ (18,637) $ (23,441) $ (38,864) $ (50,309)
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (40,027) $ (48,437)
Adjustment to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 5,317 6,627
Depreciation expense 236 253
Amortization of premium on investments 130 365
Noncash rent expense 1,388 1,371
Loss on disposal of property and equipment 0 3
Loss on sale of equipment 37 0
Changes in current assets and liabilities:    
Prepaid expenses and other current assets 1,434 (1,751)
Other non-current assets 0 6
Accounts payable 826 (1,885)
Accrued expenses and other current liabilities (2,223) (1,836)
Non-current operating lease liabilities (1,517) (1,383)
Net cash used in operating activities (34,399) (46,667)
Cash flows from investing activities:    
Purchases of equipment 0 (200)
Proceeds from sale of equipment 95 0
Proceeds from sales and maturities of investments 41,886 57,241
Purchases of investments 0 (20,504)
Net cash provided by investing activities 41,981 36,537
Cash flows from financing activities:    
Proceeds from exercise of common stock options and ESPP 51 153
Net cash provided by financing activities 51 153
Net increase (decrease) in cash and cash equivalents 7,633 (9,977)
Cash, cash equivalents and restricted cash, beginning of period 35,483 67,022
Cash, cash equivalents and restricted cash, end of period 43,116 57,045
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents    
Cash and cash equivalents, end of period 41,888 55,877
Restricted cash, end of period 1,228 1,168
Cash, cash equivalents and restricted cash, end of period 43,116 57,045
Supplemental disclosure of non-cash investing and financing activities:    
Purchases of equipment included in accounts payable and accrued expenses 34 0
Right-of-use assets obtained in exchange for operating lease obligation $ 0 $ 109
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2021   36,234,624      
Beginning balance at Dec. 31, 2021 $ 195,900 $ 5 $ 440,129 $ (414) $ (243,820)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of common stock options (in shares)   3,565      
Exercise of common stock options 11   11    
Vesting of restricted stock units (in shares)   5,000      
Issuance of common stock related to ESPP (in shares)   31,341      
Issuance of common stock related to ESPP 142   142    
Stock-based compensation (in shares)   13,038      
Stock-based compensation 3,375   3,375    
Unrealized gain (loss) on investments (1,361)     (1,361)  
Net loss (25,507)       (25,507)
Ending balance (in shares) at Mar. 31, 2022   36,287,568      
Ending balance at Mar. 31, 2022 172,560 $ 5 443,657 (1,775) (269,327)
Beginning balance (in shares) at Dec. 31, 2021   36,234,624      
Beginning balance at Dec. 31, 2021 195,900 $ 5 440,129 (414) (243,820)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Unrealized gain (loss) on investments (1,872)        
Net loss (48,437)        
Ending balance (in shares) at Jun. 30, 2022   36,315,737      
Ending balance at Jun. 30, 2022 152,371 $ 5 446,909 (2,286) (292,257)
Beginning balance (in shares) at Mar. 31, 2022   36,287,568      
Beginning balance at Mar. 31, 2022 172,560 $ 5 443,657 (1,775) (269,327)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Vesting of restricted stock units (in shares)   3,333      
Stock-based compensation (in shares)   24,836      
Stock-based compensation 3,252   3,252    
Unrealized gain (loss) on investments (511)     (511)  
Net loss (22,930)       (22,930)
Ending balance (in shares) at Jun. 30, 2022   36,315,737      
Ending balance at Jun. 30, 2022 $ 152,371 $ 5 446,909 (2,286) (292,257)
Beginning balance (in shares) at Dec. 31, 2022 36,434,297 36,434,297      
Beginning balance at Dec. 31, 2022 $ 115,695 $ 5 452,503 (1,824) (334,989)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Vesting of restricted stock units (in shares)   23,575      
Surrender of shares for taxes (in shares)   (3,903)      
Issuance of common stock related to ESPP (in shares)   33,202      
Issuance of common stock related to ESPP 51   51    
Stock-based compensation (in shares)   24,776      
Stock-based compensation 2,671   2,671    
Unrealized gain (loss) on investments 648     648  
Net loss (20,875)       (20,875)
Ending balance (in shares) at Mar. 31, 2023   36,511,947      
Ending balance at Mar. 31, 2023 $ 98,190 $ 5 455,225 (1,176) (355,864)
Beginning balance (in shares) at Dec. 31, 2022 36,434,297 36,434,297      
Beginning balance at Dec. 31, 2022 $ 115,695 $ 5 452,503 (1,824) (334,989)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Unrealized gain (loss) on investments 1,163        
Net loss $ (40,027)        
Ending balance (in shares) at Jun. 30, 2023 36,533,525 36,533,525      
Ending balance at Jun. 30, 2023 $ 82,199 $ 5 457,871 (661) (375,016)
Beginning balance (in shares) at Mar. 31, 2023   36,511,947      
Beginning balance at Mar. 31, 2023 98,190 $ 5 455,225 (1,176) (355,864)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Vesting of restricted stock units (in shares)   1,875      
Stock-based compensation (in shares)   19,703      
Stock-based compensation 2,646   2,646    
Unrealized gain (loss) on investments 515     515  
Net loss $ (19,152)       (19,152)
Ending balance (in shares) at Jun. 30, 2023 36,533,525 36,533,525      
Ending balance at Jun. 30, 2023 $ 82,199 $ 5 $ 457,871 $ (661) $ (375,016)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.2
NATURE OF BUSINESS AND BASIS OF PRESENTATION
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF BUSINESS AND BASIS OF PRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION
Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $500 million. The Company simultaneously entered into an Open Market Sale AgreementSM with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of June 30, 2023, no sales have been made pursuant to the ATM Program.
On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71.6 million, after deducting underwriting discounts and commissions, as well as other offering expenses.
The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred stock and common stock. The Company expects to continue to generate operating losses for the foreseeable future.
As of August 11, 2023, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.
The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
The Company continues to monitor the impact of global economic developments, political unrest, high inflation, the recent failure of certain banks and financial institutions, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company’s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at June 30, 2023 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$33,253 $— $— $33,253 
Investments:
Corporate bonds— 21,474 — 21,474 
U.S. Government agencies— 26,165 — 26,165 
Total$33,253 $47,639 $— $80,892 

Fair value measurements at December 31, 2022 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$32,278 $— $— $32,278 
Investments:
Commercial paper— 3,747 — 3,747 
Corporate bonds— 45,643 — 45,643 
U.S. Government agencies— 39,102 — 39,102 
Total$32,278 $88,492 $— $120,770 
When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument.
There were no transfers in or out of Level 3 categories in the periods presented.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENTS
 6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
INVESTMENTS INVESTMENTS
As of June 30, 2023, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Corporate bonds$21,765 $— $(291)$21,474 
U.S. Government agencies26,535 — (370)26,165 
Total$48,300 $— $(661)$47,639 
As of December 31, 2022, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$3,748 $— $(1)$3,747 
Corporate bonds46,443 — (800)45,643 
U.S. Government agencies40,125 — (1,023)39,102 
Total$90,316 $— $(1,824)$88,492 
As of June 30, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for corporate bonds with a fair value of $1,994 that had maturities of one to three years. As of June 30, 2023, all marketable securities held by the Company were in a loss position.
As of December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds, and commercial paper with a fair value of $13,687 that had maturities of one to three years. As of December 31, 2022, all marketable securities held by the Company were in a loss position.
As of June 30, 2023, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments. The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss. There have been no impairments of the Company’s assets measured and carried at fair value during the six months ended June 30, 2023 and the year ended December 31, 2022.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT
 6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
Property and equipment, net consisted of the following:

June 30,
2023

December 31,
2022
Laboratory equipment$645 $770 
Furniture and fixtures17 17 
Computer and office equipment38 38 
Leasehold improvements2,512 2,512 
Property and equipment3,212 3,337 
Less: accumulated depreciation(959)(750)
Total Property and Equipment, net$2,253 $2,587 

Depreciation expense for the six months ended June 30, 2023 and 2022 was $236 and $253, respectively.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
EQUITY METHOD INVESTMENT
 6 Months Ended
Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
EQUITY METHOD INVESTMENT EQUITY METHOD INVESTMENT
In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of June 30, 2023, the Company has a 39.1% voting interest in Launchpad and one seat on Launchpad’s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company.
The Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Launchpad common shares of $2,250 in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&D) had zero basis on the Company’s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&D of $2,232 in the consolidated statements of operations and comprehensive loss. The Company also recognized a loss from investments in equity method investee of $1,540 in the consolidated statement of operations and comprehensive loss, associated with the Company’s proportionate share of Launchpad’s losses. The assets contributed by the Company were principally IPR&D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $710 was substantially related to IPR&D and immediately expensed it. As of December 31, 2022, the carrying value of the investment in Launchpad was reduced to zero. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of June 30, 2023, the carrying value of the investment in Launchpad was zero.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
 6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following:

June 30,
2023

December 31,
2022
Contracted research services$3,829 $4,713 
Payroll and related expenses2,998 4,648 
Professional and consulting fees1,359 1,182 
Current portion of operating lease liability2,975 2,841 
Total accrued expenses and other current liabilities$11,161 $13,384 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
2020 Stock Option and Incentive Plan
The 2020 Stock Option and Incentive Plan (the 2020 Plan) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (IPO) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2023, 1,457,371 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2022, were added to the 2020 Plan.
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (the 2020 ESPP) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2023.
Stock-based compensation expense
The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2023202220232022
Stock options$2,475 $3,000 $4,930 $6,193 
Restricted stock units80 189 191 310 
Employee Stock Purchase Plan and Other91 63 196 124 

$2,646 $3,252 $5,317 $6,627 
For the six months ended June 30, 2023, the Company issued 44,479 shares of common stock out of its 2020 Plan under its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2023

202220232022
Research and development$833 

$1,526 $1,782 $3,054 
General and administrative1,813 

1,726 3,535 3,573 

$2,646 

$3,252 $5,317 $6,627 
Options
The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20225,359,400 $12.40 7.8$76 
Granted3,226,650 $2.70 
Cancelled or forfeited(350,424)$10.61 
Expired(68,124)$28.26 
Outstanding June 30, 20238,167,502 $8.51 8.3$11,313 
Options vested or expected to vest at June 30, 20238,167,502 $8.51 8.3$11,313 
Options exercisable at June 30, 20233,265,021 $13.61 6.9$1,610 
For the six months ended June 30, 2023, total unrecognized compensation cost related to the unvested stock-options was $15,169, which is expected to be recognized over a weighted average period of 2.2 years.
Restricted stock units
The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2023:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 2022101,397 $5.92 
Vested(15,834)$13.25 
Cancelled or forfeited(8,309)$2.14 
Unvested restricted common stock as of June 30, 202377,254 $4.82 
The total fair value of time-based restricted stock units vested during the six months ended June 30, 2023 was $210.
For the six months ended June 30, 2023, total unrecognized compensation cost related to the time-based unvested restricted stock units was $117, which is expected to be recognized over a weighted average period of 0.7 years.
The Company had 239,475 performance restricted stock units outstanding at the year ended December 31, 2022. For the six months ended June 30, 2023, the Company granted no performance restricted stock units to its employees related to the achievement of certain clinical development and/or financing milestones, released 9,616 performance restricted stock units due to the achievement of certain milestones, expired 193,000 performance restricted stock units, and had no performance restricted stock units forfeited. As of June 30, 2023, the Company had 36,859 performance restricted stock units outstanding.

Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.
As of June 30, 2023, for performance-based restricted stock units that were outstanding, the achievement of milestones was considered probable for 17,859 shares.
As of June 30, 2023, two milestones for outstanding performance restricted stock units were achieved. For the six months ended June 30, 2023, the Company recognized stock-based compensation expense related to these milestones of $45. The milestones that had not been met were considered not probable, and therefore no expense had been recognized related to these awards in the six months ended June 30, 2023.
Employee stock purchase plan
The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.
During the six months ended June 30, 2023 and 2022, there were 33,202 and 31,341 shares, respectively, issued under the 2020 ESPP.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.2
NET LOSS PER SHARE
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
Net loss per share
The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):

Three Months Ended
June 30,		Six Months Ended
June 30,

2023

202220232022
Net loss$(19,152)

$(22,930)$(40,027)$(48,437)
Weighted average common shares outstanding, basic and diluted36,516,114 

36,293,856 36,500,085 36,282,636 
Net loss per share, basic and diluted$(0.52)

$(0.63)$(1.09)$(1.33)

The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Six Months Ended
June 30,

20232022
Options to purchase common stock8,167,502 6,025,594 
Unvested restricted stock77,254 208,129 
Shares issuable under employee stock purchase plan102,351 27,572 
Unvested performance restricted stock units36,859 267,125 
Warrants to purchase common stock10,757 10,757 

8,394,723 6,539,177 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES
 6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
LEASES LEASES
The Company has historically entered into lease arrangements for its facilities. As of June 30, 2023, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options.
Operating leases
In July 2020, the Company entered into a seven-year agreement with an option to extend for five additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates.
In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for five additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2023 and 2022:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Lease Cost
Operating lease cost$1,054 $1,057 $2,108 $2,116 
Short-term lease cost11 21 28 40 
Variable lease cost126 219 382 476 
Sublease income(335)— (470)— 
Total lease cost$856 $1,297 $2,048 $2,632 
Other Operating Lease InformationJune 30, 2023June 30, 2022
Cash paid for amounts included in the measurement of lease liability$2,103 $1,290 
Weighted-average remaining lease term7.48.3
Weighted-average discount rate5.3 %5.3 %
The variable lease costs for the three and six months ended June 30, 2023 and 2022 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
Future minimum lease payments under the Company’s operating leases as of June 30, 2023 were as follows:
As of June 30, 2023
2023 (excluding the six months ended June 30, 2023)
$2,141 
20244,359 
20254,477 
20264,599 
20274,724 
Thereafter12,250 
Total lease payments32,550 
Less: interest(5,793)
Total lease liability$26,757 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.
License agreements
The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2023, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2023 or December 31, 2022.
Legal proceedings
The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.2
BENEFIT PLANS
 6 Months Ended
Jun. 30, 2023
Retirement Benefits [Abstract]  
BENEFIT PLANS BENEFIT PLANSThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three and six months ended June 30, 2023 and 2022, the Company contributed $167, $543, $199 and $757, respectively, to the 401(k) Plan.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS
 6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTSOn July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71,565, after deducting underwriting discounts and commissions, as well as other offering expenses.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Principles of consolidation and unaudited interim financial information
Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Principles of consolidation Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Use of estimates Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at June 30, 2023 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$33,253 $— $— $33,253 
Investments:
Corporate bonds— 21,474 — 21,474 
U.S. Government agencies— 26,165 — 26,165 
Total$33,253 $47,639 $— $80,892 

Fair value measurements at December 31, 2022 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$32,278 $— $— $32,278 
Investments:
Commercial paper— 3,747 — 3,747 
Corporate bonds— 45,643 — 45,643 
U.S. Government agencies— 39,102 — 39,102 
Total$32,278 $88,492 $— $120,770 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENTS (Tables)
 6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Marketable Securities
As of June 30, 2023, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Corporate bonds$21,765 $— $(291)$21,474 
U.S. Government agencies26,535 — (370)26,165 
Total$48,300 $— $(661)$47,639 
As of December 31, 2022, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$3,748 $— $(1)$3,747 
Corporate bonds46,443 — (800)45,643 
U.S. Government agencies40,125 — (1,023)39,102 
Total$90,316 $— $(1,824)$88,492 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT (Tables)
 6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment Property and equipment, net consisted of the following:

June 30,
2023

December 31,
2022
Laboratory equipment$645 $770 
Furniture and fixtures17 17 
Computer and office equipment38 38 
Leasehold improvements2,512 2,512 
Property and equipment3,212 3,337 
Less: accumulated depreciation(959)(750)
Total Property and Equipment, net$2,253 $2,587 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
 6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses Accrued expenses and other current liabilities consisted of the following:

June 30,
2023

December 31,
2022
Contracted research services$3,829 $4,713 
Payroll and related expenses2,998 4,648 
Professional and consulting fees1,359 1,182 
Current portion of operating lease liability2,975 2,841 
Total accrued expenses and other current liabilities$11,161 $13,384 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2023202220232022
Stock options$2,475 $3,000 $4,930 $6,193 
Restricted stock units80 189 191 310 
Employee Stock Purchase Plan and Other91 63 196 124 

$2,646 $3,252 $5,317 $6,627 
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2023

202220232022
Research and development$833 

$1,526 $1,782 $3,054 
General and administrative1,813 

1,726 3,535 3,573 

$2,646 

$3,252 $5,317 $6,627 
Schedule of Stock Option Activity The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20225,359,400 $12.40 7.8$76 
Granted3,226,650 $2.70 
Cancelled or forfeited(350,424)$10.61 
Expired(68,124)$28.26 
Outstanding June 30, 20238,167,502 $8.51 8.3$11,313 
Options vested or expected to vest at June 30, 20238,167,502 $8.51 8.3$11,313 
Options exercisable at June 30, 20233,265,021 $13.61 6.9$1,610 
Schedule of Restricted Stock Activity The following table summarizes time-based restricted stock activity since January 1, 2023:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 2022101,397 $5.92 
Vested(15,834)$13.25 
Cancelled or forfeited(8,309)$2.14 
Unvested restricted common stock as of June 30, 202377,254 $4.82 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.2
NET LOSS PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Computation of Net Loss per Share The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):

Three Months Ended
June 30,		Six Months Ended
June 30,

2023

202220232022
Net loss$(19,152)

$(22,930)$(40,027)$(48,437)
Weighted average common shares outstanding, basic and diluted36,516,114 

36,293,856 36,500,085 36,282,636 
Net loss per share, basic and diluted$(0.52)

$(0.63)$(1.09)$(1.33)
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Six Months Ended
June 30,

20232022
Options to purchase common stock8,167,502 6,025,594 
Unvested restricted stock77,254 208,129 
Shares issuable under employee stock purchase plan102,351 27,572 
Unvested performance restricted stock units36,859 267,125 
Warrants to purchase common stock10,757 10,757 

8,394,723 6,539,177 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES (Tables)
 6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Summary of Lease Cost and Other Operating Lease Information The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2023 and 2022:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Lease Cost
Operating lease cost$1,054 $1,057 $2,108 $2,116 
Short-term lease cost11 21 28 40 
Variable lease cost126 219 382 476 
Sublease income(335)— (470)— 
Total lease cost$856 $1,297 $2,048 $2,632 
Other Operating Lease InformationJune 30, 2023June 30, 2022
Cash paid for amounts included in the measurement of lease liability$2,103 $1,290 
Weighted-average remaining lease term7.48.3
Weighted-average discount rate5.3 %5.3 %
Schedule of Future Minimum Lease Payments Future minimum lease payments under the Company’s operating leases as of June 30, 2023 were as follows:
As of June 30, 2023
2023 (excluding the six months ended June 30, 2023)
$2,141 
20244,359 
20254,477 
20264,599 
20274,724 
Thereafter12,250 
Total lease payments32,550 
Less: interest(5,793)
Total lease liability$26,757 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.2
NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) - USD ($)
$ / shares in Units, $ in Millions
Jul. 05, 2023
Nov. 14, 2022
Shelf Registration Statement    
Subsidiary, Sale of Stock [Line Items]    
Sale of stock, authorized consideration   $ 500
Open Market Sale    
Subsidiary, Sale of Stock [Line Items]    
Sale of stock, authorized consideration   $ 150
Follow-on Offering | Subsequent Event    
Subsidiary, Sale of Stock [Line Items]    
Number of shares sold (in shares) 15,000,000  
Stock price (in dollars per share) $ 5.00  
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Assets:    
Total $ 80,892 $ 120,770
Money market funds    
Assets:    
Cash equivalents: 33,253 32,278
Commercial paper    
Assets:    
Investments:   3,747
Corporate bonds    
Assets:    
Investments: 21,474 45,643
U.S. Government agencies    
Assets:    
Investments: 26,165 39,102
Level 1    
Assets:    
Total 33,253 32,278
Level 1 | Money market funds    
Assets:    
Cash equivalents: 33,253 32,278
Level 1 | Commercial paper    
Assets:    
Investments:   0
Level 1 | Corporate bonds    
Assets:    
Investments: 0 0
Level 1 | U.S. Government agencies    
Assets:    
Investments: 0 0
Level 2    
Assets:    
Total 47,639 88,492
Level 2 | Money market funds    
Assets:    
Cash equivalents: 0 0
Level 2 | Commercial paper    
Assets:    
Investments:   3,747
Level 2 | Corporate bonds    
Assets:    
Investments: 21,474 45,643
Level 2 | U.S. Government agencies    
Assets:    
Investments: 26,165 39,102
Level 3    
Assets:    
Total 0 0
Level 3 | Money market funds    
Assets:    
Cash equivalents: 0 0
Level 3 | Commercial paper    
Assets:    
Investments:   0
Level 3 | Corporate bonds    
Assets:    
Investments: 0 0
Level 3 | U.S. Government agencies    
Assets:    
Investments: $ 0 $ 0
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENTS - Schedule of Marketable Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 48,300 $ 90,316
Unrealized Gains 0 0
Unrealized Losses (661) (1,824)
Fair Value 47,639 88,492
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   3,748
Unrealized Gains   0
Unrealized Losses   (1)
Fair Value   3,747
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 21,765 46,443
Unrealized Gains 0 0
Unrealized Losses (291) (800)
Fair Value 21,474 45,643
U.S. Government agencies    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 26,535 40,125
Unrealized Gains 0 0
Unrealized Losses (370) (1,023)
Fair Value $ 26,165 $ 39,102
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENTS - Additional Information (Details) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]    
Fair value $ 1,994,000 $ 13,687,000
Impairment of fair value assets $ 0 $ 0
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]      
Property and equipment $ 3,212   $ 3,337
Less: accumulated depreciation (959)   (750)
Total Property and Equipment, net 2,253   2,587
Depreciation expense 236 $ 253  
Laboratory equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment 645   770
Furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Property and equipment 17   17
Computer and office equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment 38   38
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment $ 2,512   $ 2,512
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.2
EQUITY METHOD INVESTMENT (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Jun. 30, 2023
Dec. 01, 2022
Schedule of Equity Method Investments [Line Items]      
Gain on sale of IP $ 2,232,000    
Research and development asset acquired other than through business combination, written-off $ 710,000    
Launchpad Therapeutics, Inc.      
Schedule of Equity Method Investments [Line Items]      
Common shares received from equity method investment (in shares) 9,000,000    
Equity method investment, ownership percentage   39.10%  
Equity method investment $ 0 $ 0 $ 2,250,000
Loss recognized from equity method investment $ 1,540,000    
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Contracted research services $ 3,829 $ 4,713
Payroll and related expenses 2,998 4,648
Professional and consulting fees 1,359 1,182
Current portion of operating lease liability 2,975 2,841
Total accrued expenses and other current liabilities $ 11,161 $ 13,384
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 01, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Jan. 14, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost, options   $ 15,169   $ 15,169      
Stock-based compensation expense   2,646 $ 3,252 $ 5,317 $ 6,627    
2020 Stock Option Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Increase of authorized shares, percent of common stock outstanding 4.00%           4.00%
Number of additional shares authorized (in shares) 1,457,371            
2020 ESPP              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Increase of authorized shares, percent of common stock outstanding             1.00%
Number of additional shares authorized (in shares) 326,364            
Stock options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost, recognition period (in years)       2 years 2 months 12 days      
Stock-based compensation expense   2,475 3,000 $ 4,930 6,193    
Stock options | 2020 Stock Option Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares issued under share-based compensation plan       44,479      
Restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost, recognition period (in years)       8 months 12 days      
Fair value of units vested       $ 210      
Unrecognized compensation cost   117   117      
Stock-based compensation expense   $ 80 $ 189 $ 191 $ 310    
Unvested performance restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Units outstanding (in shares)           239,475  
Units vested (in shares)       9,616      
Achievement of milestones probable ( in shares)   17,859   17,859      
Stock-based compensation expense       $ 45      
Performance Restricted Stock Units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Units outstanding (in shares)   36,859   36,859      
Granted (in shares)       0      
Expired performance restricted stock units (in shares)       193,000      
Forfeited (in shares)       0      
Stock-based compensation expense       $ 0      
Shares issuable under employee stock purchase plan | 2020 ESPP              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares issued under share-based compensation plan       33,202 31,341    
Award purchase period (in months)       6 months      
Maximum percent of fair market value of common stock       85.00%      
Maximum employee subscription rate   10.00%   10.00%      
Maximum employee subscription amount       $ 25      
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 2,646 $ 3,252 $ 5,317 $ 6,627
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 833 1,526 1,782 3,054
General and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 1,813 1,726 3,535 3,573
Stock options        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 2,475 3,000 4,930 6,193
Restricted stock units        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 80 189 191 310
Employee Stock Purchase Plan and Other        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 91 $ 63 $ 196 $ 124
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Options    
Outstanding, beginning balance (in shares) 5,359,400  
Granted (in shares) 3,226,650  
Canceled or forfeited (in shares) (350,424)  
Expired (in shares) (68,124)  
Outstanding, ending balance (in shares) 8,167,502 5,359,400
Options vested or expected to vest (in shares) 8,167,502  
Options exercisable (in shares) 3,265,021  
Weighted Average Exercise Price    
Outstanding, beginning balance (in dollars per share) $ 12.40  
Granted (in dollars per share) 2.70  
Cancelled or forfeited (in dollars per share) 10.61  
Expired (in dollars per share) 28.26  
Outstanding, ending balance (in dollars per share) 8.51 $ 12.40
Options vested or expected to vest (in dollars per share) 8.51  
Options exercisable (in dollars per share) $ 13.61  
Weighted Average Remaining Life and Intrinsic Value    
Options outstanding, remaining life (in years) 8 years 3 months 18 days 7 years 9 months 18 days
Options vested or expected to vest, remaining life (in years) 8 years 3 months 18 days  
Options exercisable, remaining life (in years) 6 years 10 months 24 days  
Options outstanding, intrinsic value $ 11,313 $ 76
Options vested or expected to vest, intrinsic value 11,313  
Options exercisable, intrinsic value $ 1,610  
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)
 6 Months Ended
Jun. 30, 2023
$ / shares
shares
Unvested restricted stock  
Number of shares  
Unvested restricted common stock, beginning balance (in shares) 101,397
Vested (in shares) (15,834)
Cancelled or forfeited (in shares) (8,309)
Unvested restricted common stock, ending balance (in shares) 77,254
Weighted average grant date fair value  
Unvested restricted common stock, beginning balance (in dollars per share) | $ / shares $ 5.92
Vested (in dollars per share) | $ / shares 13.25
Cancelled or forfeited (in dollars per share) | $ / shares 2.14
Unvested restricted common stock, ending balance (in dollars per share) | $ / shares $ 4.82
Unvested performance restricted stock units  
Number of shares  
Unvested restricted common stock, beginning balance (in shares) 239,475
Vested (in shares) (9,616)
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.2
NET LOSS PER SHARE - Computation of Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share [Abstract]            
Net loss $ (19,152) $ (20,875) $ (22,930) $ (25,507) $ (40,027) $ (48,437)
Weighted average common shares outstanding, basic (in shares) 36,516,114   36,293,856   36,500,085 36,282,636
Weighted average common shares outstanding, diluted (in shares) 36,516,114   36,293,856   36,500,085 36,282,636
Net loss per share, basic (in dollars per share) $ (0.52)   $ (0.63)   $ (1.09) $ (1.33)
Net loss per share, diluted (in dollars per share) $ (0.52)   $ (0.63)   $ (1.09) $ (1.33)
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.2
NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) - shares
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 8,394,723 6,539,177
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 8,167,502 6,025,594
Unvested restricted stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 77,254 208,129
Shares issuable under employee stock purchase plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 102,351 27,572
Unvested performance restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 36,859 267,125
Warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 10,757 10,757
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES - Narrative (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
contract
Dec. 31, 2020
ft²
Jul. 31, 2020
USD ($)
ft²
Lessee, Lease, Description [Line Items]      
Number of leases | contract 2    
Principal office, lease two      
Lessee, Lease, Description [Line Items]      
Lease term (in years)     7 years
Lease term, optional extension (in years)     5 years
Area leased (square feet)     25,578
Letter of credit outstanding | $     $ 1,168
Operating Lease, Office and Laboratory Space, NY      
Lessee, Lease, Description [Line Items]      
Lease term (in years)   11 years  
Lease term, optional extension (in years)   5 years  
Area leased (square feet)   18,120  
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Lease Cost        
Operating lease cost $ 1,054 $ 1,057 $ 2,108 $ 2,116
Short-term lease cost 11 21 28 40
Variable lease cost 126 219 382 476
Sublease income (335) 0 (470) 0
Total lease cost $ 856 $ 1,297 2,048 2,632
Other Operating Lease Information        
Cash paid for amounts included in the measurement of lease liability     $ 2,103 $ 1,290
Weighted-average remaining lease term (in years) 7 years 4 months 24 days 8 years 3 months 18 days 7 years 4 months 24 days 8 years 3 months 18 days
Weighted-average discount rate 5.30% 5.30% 5.30% 5.30%
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES - Schedule of Future Minimum Lease Payments (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]  
2023 (excluding the six months ended June 30, 2023) $ 2,141
2024 4,359
2025 4,477
2026 4,599
2027 4,724
Thereafter 12,250
Total lease payments 32,550
Less: interest (5,793)
Total lease liability $ 26,757
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.2
BENEFIT PLANS (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Retirement Benefits [Abstract]        
Employer contribution, matching contribution percentage     100.00%  
Employer contribution, percent of each participant's salary     6.00%  
Employer contribution amount $ 167 $ 199 $ 543 $ 757
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS (Details) - Subsequent Event - Follow-on Offering
$ / shares in Units, $ in Thousands
Jul. 05, 2023
USD ($)
$ / shares
shares
Subsequent Event [Line Items]  
Number of shares sold (in shares) | shares 15,000,000
Proceeds from equity financing | $ $ 71,565
Stock price (in dollars per share) | $ / shares $ 5.00
XML 55 bdtx-20230630_htm.xml IDEA: XBRL DOCUMENT 0001701541 2023-01-01 2023-06-30 0001701541 2023-08-01 0001701541 2023-06-30 0001701541 2022-12-31 0001701541 2023-04-01 2023-06-30 0001701541 2022-04-01 2022-06-30 0001701541 2022-01-01 2022-06-30 0001701541 2021-12-31 0001701541 2022-06-30 0001701541 us-gaap:CommonStockMember 2021-12-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001701541 us-gaap:RetainedEarningsMember 2021-12-31 0001701541 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001701541 2022-01-01 2022-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001701541 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001701541 us-gaap:CommonStockMember 2022-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001701541 us-gaap:RetainedEarningsMember 2022-03-31 0001701541 2022-03-31 0001701541 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001701541 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001701541 us-gaap:CommonStockMember 2022-06-30 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001701541 us-gaap:RetainedEarningsMember 2022-06-30 0001701541 us-gaap:CommonStockMember 2022-12-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001701541 us-gaap:RetainedEarningsMember 2022-12-31 0001701541 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001701541 2023-01-01 2023-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001701541 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001701541 us-gaap:CommonStockMember 2023-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001701541 us-gaap:RetainedEarningsMember 2023-03-31 0001701541 2023-03-31 0001701541 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001701541 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001701541 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001701541 us-gaap:CommonStockMember 2023-06-30 0001701541 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001701541 us-gaap:RetainedEarningsMember 2023-06-30 0001701541 bdtx:ShelfRegistrationStatementMember 2022-11-14 2022-11-14 0001701541 bdtx:OpenMarketSaleMember 2022-11-14 2022-11-14 0001701541 us-gaap:SubsequentEventMember bdtx:FollowOnOfferingMember 2023-07-05 2023-07-05 0001701541 us-gaap:SubsequentEventMember bdtx:FollowOnOfferingMember 2023-07-05 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001701541 us-gaap:CorporateBondSecuritiesMember 2023-06-30 0001701541 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001701541 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001701541 us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001701541 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001701541 2022-01-01 2022-12-31 0001701541 us-gaap:EquipmentMember 2023-06-30 0001701541 us-gaap:EquipmentMember 2022-12-31 0001701541 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001701541 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001701541 us-gaap:OfficeEquipmentMember 2023-06-30 0001701541 us-gaap:OfficeEquipmentMember 2022-12-31 0001701541 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001701541 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001701541 bdtx:LaunchpadTherapeuticsIncMember 2022-12-31 0001701541 bdtx:LaunchpadTherapeuticsIncMember 2023-06-30 0001701541 bdtx:LaunchpadTherapeuticsIncMember 2022-12-01 0001701541 bdtx:LaunchpadTherapeuticsIncMember 2022-01-01 2022-12-31 0001701541 bdtx:A2020StockOptionPlanMember 2020-01-14 0001701541 bdtx:A2020StockOptionPlanMember 2023-01-01 2023-01-01 0001701541 bdtx:A2020StockOptionPlanMember 2023-01-01 0001701541 bdtx:A2020EmployeeStockPurchasePlanMember 2020-01-14 0001701541 bdtx:A2020EmployeeStockPurchasePlanMember 2023-01-01 2023-01-01 0001701541 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001701541 bdtx:OtherAwardTypeMember 2023-04-01 2023-06-30 0001701541 bdtx:OtherAwardTypeMember 2022-04-01 2022-06-30 0001701541 bdtx:OtherAwardTypeMember 2023-01-01 2023-06-30 0001701541 bdtx:OtherAwardTypeMember 2022-01-01 2022-06-30 0001701541 us-gaap:EmployeeStockOptionMember bdtx:A2020StockOptionPlanMember 2023-01-01 2023-06-30 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001701541 us-gaap:RestrictedStockMember 2022-12-31 0001701541 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001701541 us-gaap:RestrictedStockMember 2023-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001701541 us-gaap:PerformanceSharesMember 2022-12-31 0001701541 bdtx:PerformanceRestrictedStockUnitsMember 2023-01-01 2023-06-30 0001701541 us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0001701541 bdtx:PerformanceRestrictedStockUnitsMember 2023-06-30 0001701541 us-gaap:PerformanceSharesMember 2023-06-30 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2023-06-30 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2022-01-01 2022-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001701541 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001701541 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001701541 us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0001701541 us-gaap:EmployeeStockMember 2022-01-01 2022-06-30 0001701541 us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0001701541 us-gaap:PerformanceSharesMember 2022-01-01 2022-06-30 0001701541 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001701541 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001701541 bdtx:OperatingLeasePrincipalOfficeTwoMember 2020-07-31 0001701541 bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember 2020-12-31 shares iso4217:USD iso4217:USD shares pure bdtx:contract utr:sqft false Q2 2023 0001701541 --12-31 http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent P5Y P5Y 10-Q true 2023-06-30 false 001-38501 BLACK DIAMOND THERAPEUTICS, INC. DE 81-4254660 One Main Street, 14th Floor Cambridge MA 02142 (617) 252-0848 Common stock, par value $0.0001 BDTX NASDAQ Yes Yes Non-accelerated Filer true true false false 51575323 41888000 34315000 47639000 88492000 3465000 4899000 92992000 127706000 2253000 2587000 1228000 1168000 23406000 24794000 119879000 156255000 2737000 1877000 11161000 13384000 13898000 15261000 23782000 25299000 37680000 40560000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 500000000 500000000 36533525 36533525 36434297 36434297 5000 5000 457871000 452503000 -661000 -1824000 -375016000 -334989000 82199000 115695000 119879000 156255000 13154000 16195000 27907000 33981000 6878000 6978000 13686000 14871000 20032000 23173000 41593000 48852000 -20032000 -23173000 -41593000 -48852000 539000 386000 1161000 792000 341000 -143000 405000 -377000 880000 243000 1566000 415000 -19152000 -22930000 -40027000 -48437000 -0.52 -0.52 -0.63 -0.63 -1.09 -1.09 -1.33 -1.33 36516114 36516114 36293856 36293856 36500085 36500085 36282636 36282636 -19152000 -22930000 -40027000 -48437000 515000 -511000 1163000 -1872000 -18637000 -23441000 -38864000 -50309000 -40027000 -48437000 5317000 6627000 236000 253000 -130000 -365000 1388000 1371000 0 -3000 -37000 0 -1434000 1751000 0 -6000 826000 -1885000 -2223000 -1836000 -1517000 -1383000 -34399000 -46667000 0 200000 95000 0 41886000 57241000 0 20504000 41981000 36537000 51000 153000 51000 153000 7633000 -9977000 35483000 67022000 43116000 57045000 41888000 55877000 1228000 1168000 43116000 57045000 34000 0 0 109000 36234624 5000 440129000 -414000 -243820000 195900000 3565 11000 11000 5000 31341 142000 142000 13038 3375000 3375000 -1361000 -1361000 -25507000 -25507000 36287568 5000 443657000 -1775000 -269327000 172560000 3333 24836 3252000 3252000 -511000 -511000 -22930000 -22930000 36315737 5000 446909000 -2286000 -292257000 152371000 36434297 5000 452503000 -1824000 -334989000 115695000 23575 3903 33202 51000 51000 24776 2671000 2671000 648000 648000 -20875000 -20875000 36511947 5000 455225000 -1176000 -355864000 98190000 1875 19703 2646000 2646000 515000 515000 -19152000 -19152000 36533525 5000 457871000 -661000 -375016000 82199000 NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $500 million. The Company simultaneously entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of June 30, 2023, no sales have been made pursuant to the ATM Program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71.6 million, after deducting underwriting discounts and commissions, as well as other offering expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred stock and common stock. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of August 11, 2023, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.</span></div>The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div> 500000000 150000000 15000000 5.00 71600000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company continues to monitor the impact of global economic developments, political unrest, high inflation, the recent failure of certain banks and financial institutions, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company’s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></div> Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. FAIR VALUE MEASUREMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at June 30, 2023 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,253 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120,770 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at June 30, 2023 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,253 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120,770 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33253000 0 0 33253000 0 21474000 0 21474000 0 26165000 0 26165000 33253000 47639000 0 80892000 32278000 0 0 32278000 0 3747000 0 3747000 0 45643000 0 45643000 0 39102000 0 39102000 32278000 88492000 0 120770000 INVESTMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,765 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(291)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(661)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">90,316 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,824)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for corporate bonds with a fair value of $1,994 that had maturities of one to three years. As of June 30, 2023, all marketable securities held by the Company were in a loss position. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds, and commercial paper with a fair value of $13,687 that had maturities of one to three years. As of December 31, 2022, all marketable securities held by the Company were in a loss position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments. The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss. There have been no impairments of the Company’s assets measured and carried at fair value during the six months ended June 30, 2023 and the year ended December 31, 2022.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,765 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(291)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(661)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">90,316 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,824)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21765000 0 291000 21474000 26535000 0 370000 26165000 48300000 0 661000 47639000 3748000 0 1000 3747000 46443000 0 800000 45643000 40125000 0 1023000 39102000 90316000 0 1824000 88492000 1994000 13687000 0 0 PROPERTY AND EQUIPMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">770 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,253 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,587 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the six months ended June 30, 2023 and 2022 was $236 and $253, respectively.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">770 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,253 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,587 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 645000 770000 17000 17000 38000 38000 2512000 2512000 3212000 3337000 959000 750000 2253000 2587000 236000 253000 EQUITY METHOD INVESTMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of June 30, 2023, the Company has a 39.1% voting interest in Launchpad and one seat on Launchpad’s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Launchpad common shares of $2,250 in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&amp;D) had zero basis on the Company’s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&amp;D of $2,232 in the consolidated statements of operations and comprehensive loss. The Company also recognized a loss from investments in equity method investee of $1,540 in the consolidated statement of operations and comprehensive loss, associated with the Company’s proportionate share of Launchpad’s losses. The assets contributed by the Company were principally IPR&amp;D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $710 was substantially related to IPR&amp;D and immediately expensed it. As of December 31, 2022, the carrying value of the investment in Launchpad was reduced to zero. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of June 30, 2023, the carrying value of the investment in Launchpad was zero.</span></div> 9000000 0.391 2250000 2232000 -1540000 710000 0 0 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-400"><span style="-sec-ix-hidden:f-401">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,384 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-400"><span style="-sec-ix-hidden:f-401">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,384 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3829000 4713000 2998000 4648000 1359000 1182000 2975000 2841000 11161000 13384000 STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Stock Option and Incentive Plan (the 2020 Plan) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (IPO) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2023, 1,457,371 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2022, were added to the 2020 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the 2020 ESPP) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,646 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, the Company issued 44,479 shares of common stock out of its 2020 Plan under its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,813 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,726 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,535 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,573 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,646 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,317 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,627 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Options </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company’s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,359,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,226,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(350,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(68,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,167,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,167,502 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,265,021 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, total unrecognized compensation cost related to the unvested stock-options was $15,169, which is expected to be recognized over a weighted average period of 2.2 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(15,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77,254 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.82 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The total fair value of time-based restricted stock units vested during the six months ended June 30, 2023 was $210. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, total unrecognized compensation cost related to the time-based unvested restricted stock units was $117, which is expected to be recognized over a weighted average period of 0.7 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company had 239,475 performance restricted stock units outstanding at the year ended December 31, 2022. For the six months ended June 30, 2023, the Company granted no performance restricted stock units to its employees related to the achievement of certain clinical development and/or financing milestones, released 9,616 performance restricted stock units due to the achievement of certain milestones, expired 193,000 performance restricted stock units, and had no performance restricted stock units forfeited. As of June 30, 2023, the Company had 36,859 performance restricted stock units outstanding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, for performance-based restricted stock units that were outstanding, the achievement of milestones was considered probable for 17,859 shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, two milestones for outstanding performance restricted stock units were achieved. For the six months ended June 30, 2023, the Company recognized stock-based compensation expense related to these milestones of $45. The milestones that had not been met were considered not probable, and therefore no expense had been recognized related to these awards in the six months ended June 30, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the six months ended June 30, 2023 and 2022, there were 33,202 and 31,341 shares, respectively, issued under the 2020 ESPP.</span></div> 0.04 1457371 0.04 0.01 326364 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,646 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,813 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,726 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,535 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,573 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,646 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,317 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,627 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2475000 3000000 4930000 6193000 80000 189000 191000 310000 91000 63000 196000 124000 2646000 3252000 5317000 6627000 44479 833000 1526000 1782000 3054000 1813000 1726000 3535000 3573000 2646000 3252000 5317000 6627000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company’s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,359,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,226,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(350,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(68,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,167,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,167,502 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,265,021 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 5359400 12.40 P7Y9M18D 76000 3226650 2.70 350424 10.61 68124 28.26 8167502 8.51 P8Y3M18D 11313000 8167502 8.51 P8Y3M18D 11313000 3265021 13.61 P6Y10M24D 1610000 15169000 P2Y2M12D The following table summarizes time-based restricted stock activity since January 1, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(15,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77,254 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.82 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 101397 5.92 15834 13.25 8309 2.14 77254 4.82 210000 117000 P0Y8M12D 239475 0 9616 193000 0 36859 17859 45000 0 P6M 0.85 0.10 25000 33202 31341 NET LOSS PER SHARE<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(19,152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(22,930)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(40,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(48,437)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,516,114 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,293,856 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,500,085 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,282,636 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.52)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.63)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,167,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,025,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">208,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested performance restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">267,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,394,723 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,539,177 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(19,152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(22,930)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(40,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(48,437)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,516,114 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,293,856 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,500,085 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,282,636 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.52)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.63)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -19152000 -22930000 -40027000 -48437000 36516114 36516114 36293856 36293856 36500085 36500085 36282636 36282636 -0.52 -0.52 -0.63 -0.63 -1.09 -1.09 -1.33 -1.33 The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,167,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,025,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">208,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested performance restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">267,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,394,723 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,539,177 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 8167502 6025594 77254 208129 102351 27572 36859 267125 10757 10757 8394723 6539177 LEASES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of June 30, 2023, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a seven-year agreement with an option to extend for <span style="-sec-ix-hidden:f-532">five</span> additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for <span style="-sec-ix-hidden:f-537">five</span> additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">856 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,297 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,048 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,632 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three and six months ended June 30, 2023 and 2022 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company’s operating leases as of June 30, 2023 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of June 30, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 (excluding the six months ended June 30, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,757 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 P7Y 25578 1168000 P11Y 18120 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">856 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,297 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,048 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,632 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table> 1054000 1057000 2108000 2116000 11000 21000 28000 40000 126000 219000 382000 476000 335000 0 470000 0 856000 1297000 2048000 2632000 2103000 1290000 P7Y4M24D P8Y3M18D 0.053 0.053 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company’s operating leases as of June 30, 2023 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of June 30, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 (excluding the six months ended June 30, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,757 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2141000 4359000 4477000 4599000 4724000 12250000 32550000 5793000 26757000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2023, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2023 or December 31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div> BENEFIT PLANSThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three and six months ended June 30, 2023 and 2022, the Company contributed $167, $543, $199 and $757, respectively, to the 401(k) Plan. 1 0.06 167000 543000 199000 757000 SUBSEQUENT EVENTSOn July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71,565, after deducting underwriting discounts and commissions, as well as other offering expenses. 15000000 5.00 71565000 EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

?'G=.�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 161 222 1 false 39 0 false 6 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.blackdiamondtherapeutics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 0000009 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 0000010 - Disclosure - INVESTMENTS Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTS INVESTMENTS Notes 10 false false R11.htm 0000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 0000012 - Disclosure - EQUITY METHOD INVESTMENT Sheet http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT EQUITY METHOD INVESTMENT Notes 12 false false R13.htm 0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 13 false false R14.htm 0000014 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 14 false false R15.htm 0000015 - Disclosure - NET LOSS PER SHARE Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 15 false false R16.htm 0000016 - Disclosure - LEASES Sheet http://www.blackdiamondtherapeutics.com/role/LEASES LEASES Notes 16 false false R17.htm 0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 0000018 - Disclosure - BENEFIT PLANS Sheet http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS BENEFIT PLANS Notes 18 false false R19.htm 0000019 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 19 false false R20.htm 9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 9954702 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS 21 false false R22.htm 9954703 - Disclosure - INVESTMENTS (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables INVESTMENTS (Tables) Tables http://www.blackdiamondtherapeutics.com/role/INVESTMENTS 22 false false R23.htm 9954704 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT 23 false false R24.htm 9954705 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES 24 false false R25.htm 9954706 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION 25 false false R26.htm 9954707 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE 26 false false R27.htm 9954708 - Disclosure - LEASES (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESTables LEASES (Tables) Tables http://www.blackdiamondtherapeutics.com/role/LEASES 27 false false R28.htm 9954709 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) Details http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION 28 false false R29.htm 9954710 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 29 false false R30.htm 9954711 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails INVESTMENTS - Schedule of Marketable Securities (Details) Details 30 false false R31.htm 9954712 - Disclosure - INVESTMENTS - Additional Information (Details) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails INVESTMENTS - Additional Information (Details) Details 31 false false R32.htm 9954713 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails PROPERTY AND EQUIPMENT (Details) Details http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables 32 false false R33.htm 9954714 - Disclosure - EQUITY METHOD INVESTMENT (Details) Sheet http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails EQUITY METHOD INVESTMENT (Details) Details http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT 33 false false R34.htm 9954715 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables 34 false false R35.htm 9954716 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 35 false false R36.htm 9954717 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) Details 36 false false R37.htm 9954718 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) Details 37 false false R38.htm 9954719 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) Details 38 false false R39.htm 9954720 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails NET LOSS PER SHARE - Computation of Net Loss per Share (Details) Details 39 false false R40.htm 9954721 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) Details 40 false false R41.htm 9954722 - Disclosure - LEASES - Narrative (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 41 false false R42.htm 9954723 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) Details 42 false false R43.htm 9954724 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails LEASES - Schedule of Future Minimum Lease Payments (Details) Details 43 false false R44.htm 9954725 - Disclosure - BENEFIT PLANS (Details) Sheet http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails BENEFIT PLANS (Details) Details http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS 44 false false R45.htm 9954726 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTS 45 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseRenewalTerm - bdtx-20230630.htm 4 bdtx-20230630.htm bdtx-20230630.xsd bdtx-20230630_cal.xml bdtx-20230630_def.xml bdtx-20230630_lab.xml bdtx-20230630_pre.xml exhibit311_q22023.htm exhibit312_q22023.htm exhibit321_q22023.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bdtx-20230630.htm": { "axisCustom": 0, "axisStandard": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 529, "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 161, "dts": { "calculationLink": { "local": [ "bdtx-20230630_cal.xml" ] }, "definitionLink": { "local": [ "bdtx-20230630_def.xml" ] }, "inline": { "local": [ "bdtx-20230630.htm" ] }, "labelLink": { "local": [ "bdtx-20230630_lab.xml" ] }, "presentationLink": { "local": [ "bdtx-20230630_pre.xml" ] }, "schema": { "local": [ "bdtx-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 349, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 4, "http://xbrl.sec.gov/dei/2023": 5, "total": 9 }, "keyCustom": 16, "keyStandard": 206, "memberCustom": 10, "memberStandard": 25, "nsprefix": "bdtx", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.blackdiamondtherapeutics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - INVESTMENTS", "menuCat": "Notes", "order": "10", "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS", "shortName": "INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - PROPERTY AND EQUIPMENT", "menuCat": "Notes", "order": "11", "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - EQUITY METHOD INVESTMENT", "menuCat": "Notes", "order": "12", "role": "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT", "shortName": "EQUITY METHOD INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "menuCat": "Notes", "order": "13", "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "14", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - NET LOSS PER SHARE", "menuCat": "Notes", "order": "15", "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE", "shortName": "NET LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - LEASES", "menuCat": "Notes", "order": "16", "role": "http://www.blackdiamondtherapeutics.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "17", "role": "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - BENEFIT PLANS", "menuCat": "Notes", "order": "18", "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS", "shortName": "BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "19", "role": "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTS", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "20", "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - INVESTMENTS (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables", "shortName": "INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - NET LOSS PER SHARE (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables", "shortName": "NET LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.blackdiamondtherapeutics.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-54", "decimals": "-6", "first": true, "lang": "en-US", "name": "bdtx:SaleOfStockAuthorizedConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "menuCat": "Details", "order": "28", "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-54", "decimals": "-6", "first": true, "lang": "en-US", "name": "bdtx:SaleOfStockAuthorizedConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-73", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "menuCat": "Details", "order": "29", "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-73", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)", "menuCat": "Details", "order": "30", "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails", "shortName": "INVESTMENTS - Schedule of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - INVESTMENTS - Additional Information (Details)", "menuCat": "Details", "order": "31", "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails", "shortName": "INVESTMENTS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "menuCat": "Details", "order": "32", "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-99", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - EQUITY METHOD INVESTMENT (Details)", "menuCat": "Details", "order": "33", "role": "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails", "shortName": "EQUITY METHOD INVESTMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-99", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "bdtx:AccruedContractResearchServiceFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "menuCat": "Details", "order": "34", "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "bdtx:AccruedContractResearchServiceFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "menuCat": "Details", "order": "35", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-114", "decimals": "2", "lang": "en-US", "name": "bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)", "menuCat": "Details", "order": "36", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-130", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-4", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)", "menuCat": "Details", "order": "37", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "0", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-138", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)", "menuCat": "Details", "order": "38", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-138", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)", "menuCat": "Details", "order": "39", "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails", "shortName": "NET LOSS PER SHARE - Computation of Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "menuCat": "Details", "order": "40", "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "bdtx:LesseeOperatingLeaseNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "contract", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - LEASES - Narrative (Details)", "menuCat": "Details", "order": "41", "role": "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "bdtx:LesseeOperatingLeaseNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "contract", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954723 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)", "menuCat": "Details", "order": "42", "role": "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails", "shortName": "LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954724 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)", "menuCat": "Details", "order": "43", "role": "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails", "shortName": "LEASES - Schedule of Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954725 - Disclosure - BENEFIT PLANS (Details)", "menuCat": "Details", "order": "44", "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails", "shortName": "BENEFIT PLANS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-56", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954726 - Disclosure - SUBSEQUENT EVENTS (Details)", "menuCat": "Details", "order": "45", "role": "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-56", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-10", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-14", "decimals": "0", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION", "menuCat": "Notes", "order": "7", "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - FAIR VALUE MEASUREMENTS", "menuCat": "Notes", "order": "9", "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 39, "tag": { "bdtx_A2020EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Employee Stock Purchase Plan", "label": "2020 Employee Stock Purchase Plan [Member]", "terseLabel": "2020 ESPP" } } }, "localname": "A2020EmployeeStockPurchasePlanMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_A2020StockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Stock Option Plan", "label": "2020 Stock Option Plan [Member]", "terseLabel": "2020 Stock Option Plan" } } }, "localname": "A2020StockOptionPlanMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_AccruedContractResearchServiceFeesCurrent": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Contract Research Service Fees, Current", "label": "Accrued Contract Research Service Fees, Current", "terseLabel": "Contracted research services" } } }, "localname": "AccruedContractResearchServiceFeesCurrent", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three", "terseLabel": "Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Shares Received in Noncash Exchange", "label": "Equity Method Investment, Shares Received in Noncash Exchange", "terseLabel": "Common shares received from equity method investment (in shares)" } } }, "localname": "EquityMethodInvestmentSharesReceivedInNoncashExchange", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "sharesItemType" }, "bdtx_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-on Offering", "label": "Follow-on Offering [Member]", "terseLabel": "Follow-on Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "bdtx_GainLossOnDisposalOfPropertyAndEquipment": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) on Disposal of Property and Equipment", "label": "Gain (Loss) on Disposal of Property and Equipment", "negatedTerseLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnDisposalOfPropertyAndEquipment", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bdtx_GainLossOnSaleOfEquipment": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) on Sale of Equipment", "label": "Gain (Loss) on Sale of Equipment", "negatedLabel": "Loss on sale of equipment" } } }, "localname": "GainLossOnSaleOfEquipment", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bdtx_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease Liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "label": "Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation" } } }, "localname": "IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bdtx_LaunchpadTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Launchpad Therapeutics, Inc.", "label": "Launchpad Therapeutics, Inc. [Member]", "terseLabel": "Launchpad Therapeutics, Inc." } } }, "localname": "LaunchpadTherapeuticsIncMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "bdtx_LeaseOtherInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, Other Information [Abstract]", "label": "Lease, Other Information [Abstract]", "terseLabel": "Other Operating Lease Information" } } }, "localname": "LeaseOtherInformationAbstract", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "bdtx_LesseeOperatingLeaseArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Area", "label": "Lessee, Operating Lease, Area", "terseLabel": "Area leased (square feet)" } } }, "localname": "LesseeOperatingLeaseArea", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "areaItemType" }, "bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_LesseeOperatingLeaseNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Contracts", "label": "Lessee, Operating Lease, Number Of Contracts", "terseLabel": "Number of leases" } } }, "localname": "LesseeOperatingLeaseNumberOfContracts", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "integerItemType" }, "bdtx_OpenMarketSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Open Market Sale", "label": "Open Market Sale [Member]", "terseLabel": "Open Market Sale" } } }, "localname": "OpenMarketSaleMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Office and Laboratory Space, NY", "label": "Operating Lease, Office and Laboratory Space, NY [Member]", "terseLabel": "Operating Lease, Office and Laboratory Space, NY" } } }, "localname": "OperatingLeaseOfficeAndLaboratorySpaceNYMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_OperatingLeasePrincipalOfficeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Principal Office, Two", "label": "Operating Lease, Principal Office, Two [Member]", "terseLabel": "Principal office, lease two" } } }, "localname": "OperatingLeasePrincipalOfficeTwoMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_OtherAwardTypeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Award Type", "label": "Other Award Type [Member]", "terseLabel": "Employee Stock Purchase Plan and Other" } } }, "localname": "OtherAwardTypeMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bdtx_PerformanceRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Restricted Stock Units", "label": "Performance Restricted Stock Units [Member]", "terseLabel": "Performance Restricted Stock Units" } } }, "localname": "PerformanceRestrictedStockUnitsMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_RentExpense": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rent Expense", "label": "Rent Expense", "terseLabel": "Noncash rent expense" } } }, "localname": "RentExpense", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bdtx_SaleOfStockAuthorizedConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Authorized Consideration", "label": "Sale of Stock, Authorized Consideration", "terseLabel": "Sale of stock, authorized consideration" } } }, "localname": "SaleOfStockAuthorizedConsideration", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding", "terseLabel": "Increase of authorized shares, percent of common stock outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable", "terseLabel": "Achievement of milestones probable ( in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount", "terseLabel": "Maximum employee subscription amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "terseLabel": "Award purchase period (in months)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "bdtx_ShelfRegistrationStatementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shelf Registration Statement", "label": "Shelf Registration Statement [Member]", "terseLabel": "Shelf Registration Statement" } } }, "localname": "ShelfRegistrationStatementMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20230630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r187", "r188", "r190" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r187", "r188", "r190" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r447" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional and consulting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r99", "r365" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r20", "r50", "r101", "r362", "r376", "r377" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r1", "r6", "r20", "r277", "r280", "r318", "r372", "r373", "r477", "r478", "r479", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r45", "r447", "r550" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r265", "r266", "r267", "r381", "r484", "r485", "r486", "r539", "r551" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r36", "r37", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r260", "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r77", "r100", "r118", "r145", "r149", "r151", "r191", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r272", "r274", "r295", "r358", "r403", "r447", "r457", "r508", "r509", "r545" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r95", "r102", "r118", "r191", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r272", "r274", "r295", "r447", "r508", "r509", "r545" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r39" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r160" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r161" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r157", "r200", "r357" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r158", "r200", "r353", "r488" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r154", "r200" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation and unaudited interim financial information" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r42", "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r23", "r24", "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r22", "r97", "r433" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, end of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r22", "r61", "r117" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash, end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r61" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r510", "r540" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper", "verboseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r40", "r359", "r390" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r69", "r207", "r208", "r432", "r507" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r484", "r485", "r539", "r549", "r551" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r44", "r391" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r44", "r391", "r409", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r44", "r361", "r447" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.0001 par value; 500,000,000 shares authorized at June\u00a030, 2023 and December\u00a031, 2022; 36,533,525 shares issued and outstanding at June\u00a030, 2023 and 36,434,297 shares issued and outstanding at December\u00a031, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r71", "r72", "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "BENEFIT PLANS" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r21", "r106", "r108", "r112", "r354", "r370" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r38", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds", "verboseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded", "terseLabel": "Impairment of fair value assets" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer contribution amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer contribution, percent of each participant's salary" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer contribution, matching contribution percentage" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r4", "r31" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r229", "r233", "r261", "r262", "r264", "r445" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r113", "r124", "r125", "r126", "r127", "r128", "r133", "r135", "r137", "r138", "r139", "r143", "r284", "r285", "r355", "r371", "r436" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)", "verboseLabel": "Net loss per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r113", "r124", "r125", "r126", "r127", "r128", "r135", "r137", "r138", "r139", "r143", "r284", "r285", "r355", "r371", "r436" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)", "verboseLabel": "Net loss per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r132", "r140", "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost, recognition period (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Shares issuable under employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Options to purchase common stock", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r93", "r109", "r110", "r111", "r119", "r120", "r121", "r123", "r129", "r131", "r144", "r193", "r194", "r222", "r265", "r266", "r267", "r270", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r296", "r297", "r298", "r299", "r300", "r301", "r318", "r372", "r373", "r374", "r381", "r429" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r147", "r186", "r474", "r505" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r91", "r189", "r192", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "EQUITY METHOD INVESTMENT" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r287", "r288", "r291" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r287", "r288", "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r218", "r223", "r224", "r225", "r226", "r227", "r228", "r288", "r325", "r326", "r327", "r440", "r441", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r287", "r288", "r289", "r290", "r292" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r218", "r223", "r228", "r288", "r325", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r218", "r223", "r228", "r288", "r326", "r440", "r441", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r218", "r223", "r224", "r225", "r226", "r227", "r228", "r288", "r327", "r440", "r441", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r218", "r223", "r224", "r225", "r226", "r227", "r228", "r325", "r326", "r327", "r440", "r441", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r286", "r292" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r195", "r196", "r197", "r198", "r199", "r201", "r202", "r203", "r219", "r221", "r282", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r369", "r439", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r501", "r502", "r503", "r504" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r481" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Gain (Loss) on Disposition of Intangible Assets", "terseLabel": "Gain on sale of IP" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r54", "r413" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r4", "r51", "r79", "r146", "r186", "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Loss recognized from equity method investment" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r205", "r206", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r206", "r414" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r3" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r480" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r480" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r3" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r56" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedTerseLabel": "Amortization of premium on investments" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r55" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r287" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments:" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r76", "r81", "r82", "r92", "r153", "r155", "r293", "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "INVESTMENTS" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r309", "r446" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Lease Cost and Other Operating Lease Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r317" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r317" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r317" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r317" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r317" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r544" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2023 (excluding the six months ended June\u00a030, 2023)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r317" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease term, optional extension (in years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term (in years)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letter of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r118", "r191", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r273", "r274", "r275", "r295", "r389", "r437", "r457", "r508", "r545", "r546" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r49", "r78", "r364", "r447", "r483", "r506", "r541" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r96", "r118", "r191", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r273", "r274", "r275", "r295", "r447", "r508", "r545", "r546" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r61", "r62", "r63" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r52", "r63", "r80", "r94", "r105", "r107", "r111", "r118", "r122", "r124", "r125", "r126", "r127", "r130", "r131", "r136", "r145", "r148", "r150", "r152", "r191", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r285", "r295", "r368", "r411", "r427", "r428", "r438", "r456", "r508" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Computer and office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r145", "r148", "r150", "r152", "r438" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r310", "r446" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r305" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r305" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r305" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r307", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liability" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r304" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r316", "r446" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r315", "r446" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r103", "r104" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on investments, net", "verboseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r59" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Unvested performance restricted stock units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r43", "r220" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r43", "r391" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r43", "r220" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r43", "r391", "r409", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r43", "r360", "r447" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June\u00a030, 2023 and December\u00a031, 2022; no shares issued or outstanding at June\u00a030, 2023 and December\u00a031, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r476" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r2", "r11" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of common stock options and ESPP" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r2", "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from equity financing" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r114", "r115", "r489" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales and maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r58" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r67", "r86", "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r68", "r98", "r366" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r356", "r366", "r447" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r30", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Writeoff", "terseLabel": "Research and development asset acquired other than through business combination, written-off" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r41", "r269", "r547" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r83", "r475", "r482" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash, end of period" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r46", "r70", "r363", "r375", "r377", "r380", "r392", "r447" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r93", "r119", "r120", "r121", "r123", "r129", "r131", "r193", "r194", "r265", "r266", "r267", "r270", "r271", "r276", "r278", "r279", "r281", "r283", "r372", "r374", "r381", "r551" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares sold (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Stock price (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Computation of Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [ "r118", "r187", "r188", "r190", "r191", "r295" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r94", "r118", "r187", "r188", "r190", "r191", "r295" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r230", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r9", "r10", "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Cancelled or forfeited (in shares)", "terseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Cancelled or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested restricted common stock, ending balance (in shares)", "periodStartLabel": "Unvested restricted common stock, beginning balance (in shares)", "terseLabel": "Units outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number\u00a0of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested restricted common stock, ending balance (in dollars per share)", "periodStartLabel": "Unvested restricted common stock, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant\u00a0date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)", "terseLabel": "Units vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of units vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r230", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum employee subscription rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "terseLabel": "Expired performance restricted stock units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Life and Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Canceled or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "periodStartLabel": "Outstanding, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options vested or expected to vest, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options vested or expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options vested or expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Shares issued under share-based compensation plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, remaining life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, remaining life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested or expected to vest, remaining life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Maximum percent of fair market value of common stock" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Surrender of shares for taxes (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r311", "r446" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r18", "r93", "r109", "r110", "r111", "r119", "r120", "r121", "r123", "r129", "r131", "r144", "r193", "r194", "r222", "r265", "r266", "r267", "r270", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r296", "r297", "r298", "r299", "r300", "r301", "r318", "r372", "r373", "r374", "r381", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r119", "r120", "r121", "r144", "r352", "r378", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r410", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r451" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r119", "r120", "r121", "r144", "r352", "r378", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r410", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r451" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r7", "r43", "r44", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock related to ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r7", "r43", "r44", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r7", "r43", "r44", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r43", "r44", "r70", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "verboseLabel": "Exercise of common stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r7", "r43", "r44", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock related to ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r7", "r18", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r44", "r47", "r48", "r66", "r393", "r409", "r430", "r431", "r447", "r457", "r483", "r506", "r541", "r551" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r313", "r446" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r302", "r320" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r302", "r320" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r302", "r320" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r302", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r302", "r320" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r319", "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r219", "r221", "r282", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r369", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r501", "r502", "r503", "r504" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r435", "r442", "r548" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government agencies", "verboseLabel": "U.S. Government agencies" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r27", "r28", "r29", "r84", "r85", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r312", "r446" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r448", "r449", "r452", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r134", "r139" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r133", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r459": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r461": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r462": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(f)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org//710/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org//712/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org//715/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//940-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//942-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//946-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org//323/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 63 0001701541-23-000041-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001701541-23-000041-xbrl.zip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�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end